{"items": "181", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office", "url": "https://www.globenewswire.com/news-release/2025/01/02/3003488/0/en/Clearmind-Medicine-Granted-Patent-for-Binge-Behavior-Treatment-by-the-Macau-International-Intellectual-Property-Office.html", "time_published": "20250102T124500", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, Jan. 02, 2025 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bd17cbf4-8124-4f86-8a4c-1fafbb6785af", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.093226, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.14573", "ticker_sentiment_score": "0.174542", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/25/01/g42762285/clearmind-medicine-granted-patent-for-binge-behavior-treatment-by-the-macau-international-intellec", "time_published": "20250102T124500", "authors": ["Globe Newswire"], "summary": "Vancouver, Canada, Jan. 02, 2025 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.107409, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.139534", "ticker_sentiment_score": "0.162351", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute", "url": "https://www.globenewswire.com/news-release/2024/12/26/3001921/0/en/Clearmind-Medicine-Looks-to-Move-Forward-with-its-Novel-Psychedelic-MEAI-Based-Alcohol-Substitute.html", "time_published": "20241226T115900", "authors": ["Clearmind Medicine Inc."], "summary": "Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal\u2122 Format ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bd17cbf4-8124-4f86-8a4c-1fafbb6785af", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.197368, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.144059", "ticker_sentiment_score": "0.210427", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Is Penny Stock Clearmind Gaining Today? - AdvisorShares Psychedelics ETF  ( ARCA:PSIL ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/general/health-care/24/12/42672992/why-is-penny-stock-clearmind-gaining-today", "time_published": "20241224T163251", "authors": ["Nabaparna Bhattacharya"], "summary": "Clearmind Medicine Inc. CMND saw its shares rise on Tuesday after announcing that it has received Institutional Review Board ( IRB ) approval for its Phase I/IIa clinical trial of CMND-100, a drug targeting alcohol use disorder ( AUD ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/24/Genetic-Research-And-Biotech-Science-Con.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.256306, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.84035", "ticker_sentiment_score": "0.369155", "ticker_sentiment_label": "Bullish"}]}, {"title": "Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial", "url": "https://www.globenewswire.com/news-release/2024/12/24/3001656/0/en/Clearmind-Medicine-Receives-IRB-Approval-for-its-FDA-Regulated-Clinical-Trial.html", "time_published": "20241224T115500", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, Dec. 24, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bd17cbf4-8124-4f86-8a4c-1fafbb6785af", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.06532, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.418689", "ticker_sentiment_score": "0.074862", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal\u2122 Format", "url": "https://www.globenewswire.com/news-release/2024/12/16/2997541/0/en/Clearmind-Medicine-and-Dr-Glitter-Pty-Ltd-Sign-Term-Sheet-for-Mutual-Development-of-Novel-Psychedelic-MEAI-Based-Alcohol-Substitute-in-ActivCrystal-Format.html", "time_published": "20241216T133700", "authors": ["Clearmind Medicine Inc."], "summary": "The term sheet is non-binding, subject to the execution of a definitive agreement ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bd17cbf4-8124-4f86-8a4c-1fafbb6785af", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.222793, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.135157", "ticker_sentiment_score": "0.202002", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal\u2122 Format - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/12/g42507585/clearmind-medicine-and-dr-glitter-pty-ltd-sign-term-sheet-for-mutual-development-of-novel-psychede", "time_published": "20241216T133700", "authors": ["Globe Newswire"], "summary": "The term sheet is non-binding, subject to the execution of a definitive agreement Vancouver, Canada, Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.22732, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.131105", "ticker_sentiment_score": "0.195235", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Aehr Test System  ( NASDAQ:AEHR ) ", "url": "https://www.benzinga.com/news/24/10/41288032/why-aehr-test-systems-shares-are-trading-higher-by-around-14-here-are-20-stocks-moving-premarket", "time_published": "20241011T102036", "authors": ["Avi Kapoor"], "summary": "Shares of Aehr Test Systems, Inc. AEHR rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results. Aehr Test Systems reported quarterly earnings of 7 cents per share, which beat the analyst consensus estimate of 2 cents.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/11/movers-image.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.115217, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MLGO", "relevance_score": "0.13347", "ticker_sentiment_score": "-0.224458", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MNTS", "relevance_score": "0.199037", "ticker_sentiment_score": "-0.045334", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDLY", "relevance_score": "0.13347", "ticker_sentiment_score": "-0.052197", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNR", "relevance_score": "0.13347", "ticker_sentiment_score": "-0.12777", "ticker_sentiment_label": "Neutral"}, {"ticker": "LKCO", "relevance_score": "0.13347", "ticker_sentiment_score": "-0.056259", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKAN", "relevance_score": "0.13347", "ticker_sentiment_score": "0.292581", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GRTS", "relevance_score": "0.199037", "ticker_sentiment_score": "0.311736", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NIVF", "relevance_score": "0.263231", "ticker_sentiment_score": "0.274726", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AEHR", "relevance_score": "0.263231", "ticker_sentiment_score": "0.273016", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INV", "relevance_score": "0.13347", "ticker_sentiment_score": "0.146878", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.13347", "ticker_sentiment_score": "-0.113746", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLXG", "relevance_score": "0.13347", "ticker_sentiment_score": "-0.139282", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMLI", "relevance_score": "0.13347", "ticker_sentiment_score": "0.187295", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZENA", "relevance_score": "0.13347", "ticker_sentiment_score": "-0.027132", "ticker_sentiment_label": "Neutral"}, {"ticker": "CETX", "relevance_score": "0.13347", "ticker_sentiment_score": "-0.056259", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUXH", "relevance_score": "0.199037", "ticker_sentiment_score": "0.314702", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LILM", "relevance_score": "0.13347", "ticker_sentiment_score": "-0.227636", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CMND", "relevance_score": "0.199037", "ticker_sentiment_score": "-0.020233", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Files International Patent For Ibogaine Combination Therapy - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/24/09/40904875/clearmind-medicine-files-international-patent-for-ibogaine-combination-therapy", "time_published": "20240917T163105", "authors": ["Juan Sp\u00ednelli"], "summary": "Clearmind Medicine Inc. CMND filed a patent application for its combination therapy involving Ibogaine and N-Acylethanolamines. What Happened: The therapy was developed in collaboration with SciSparc Ltd.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/17/1-14.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.258238, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.441698", "ticker_sentiment_score": "0.406337", "ticker_sentiment_label": "Bullish"}, {"ticker": "CMND", "relevance_score": "0.339356", "ticker_sentiment_score": "0.401188", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Ocean Power Techs  ( AMEX:OPTT ) ", "url": "https://www.benzinga.com/news/24/09/40893104/why-intel-shares-are-trading-higher-by-around-7-here-are-20-stocks-moving-premarket", "time_published": "20240917T094813", "authors": ["Avi Kapoor"], "summary": "Shares of Intel Corporation INTC rose sharply in today's pre-market trading after the company announced a strategic collaboration with AWS to help advance US-based chip manufacturing. Intel shares jumped 6.9% to $22.36 in the pre-market trading. Here are some other stocks moving in pre-market ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/17/movers-image.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.897321"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.125456, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CNEY", "relevance_score": "0.235062", "ticker_sentiment_score": "0.113786", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKGN", "relevance_score": "0.235062", "ticker_sentiment_score": "0.080369", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZVSA", "relevance_score": "0.158", "ticker_sentiment_score": "-0.015863", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRMA", "relevance_score": "0.158", "ticker_sentiment_score": "-0.157352", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BBLG", "relevance_score": "0.158", "ticker_sentiment_score": "-0.062406", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRC", "relevance_score": "0.235062", "ticker_sentiment_score": "0.147318", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLR", "relevance_score": "0.158", "ticker_sentiment_score": "0.320521", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.079392", "ticker_sentiment_score": "-0.17001", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NCPL", "relevance_score": "0.158", "ticker_sentiment_score": "-0.246581", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "APVO", "relevance_score": "0.158", "ticker_sentiment_score": "-0.170508", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "INTC", "relevance_score": "0.235062", "ticker_sentiment_score": "0.229416", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SMSI", "relevance_score": "0.158", "ticker_sentiment_score": "-0.219103", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ADGM", "relevance_score": "0.158", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYNA", "relevance_score": "0.158", "ticker_sentiment_score": "0.403075", "ticker_sentiment_label": "Bullish"}, {"ticker": "GDHG", "relevance_score": "0.158", "ticker_sentiment_score": "0.145103", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLMD", "relevance_score": "0.158", "ticker_sentiment_score": "-0.030121", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGR", "relevance_score": "0.158", "ticker_sentiment_score": "0.159984", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNON", "relevance_score": "0.158", "ticker_sentiment_score": "-0.08796", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.079392", "ticker_sentiment_score": "0.085288", "ticker_sentiment_label": "Neutral"}, {"ticker": "WHLR", "relevance_score": "0.158", "ticker_sentiment_score": "0.19417", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy", "url": "https://www.globenewswire.com/news-release/2024/09/16/2947021/0/en/SciSparc-Clearmind-Medicine-Collaboration-Announces-the-Publication-of-an-International-Patent-Application-for-Pioneering-Ibogaine-Combination-Therapy.html", "time_published": "20240916T200600", "authors": ["SciSparc Ltd"], "summary": "This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.16318, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.403172", "ticker_sentiment_score": "0.161585", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.179343", "ticker_sentiment_score": "0.117249", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy", "url": "https://www.globenewswire.com/news-release/2024/09/16/2947020/0/en/Clearmind-Medicine-Announces-the-Notice-of-an-International-Patent-Application-for-Pioneering-Ibogaine-Combination-Therapy.html", "time_published": "20240916T200600", "authors": ["Clearmind Medicine Inc."], "summary": "Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in mental health and addiction care ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/52c0fa73-1317-4a42-bfa5-ea0252669a70", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.191787, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.239698", "ticker_sentiment_score": "0.237612", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.16117", "ticker_sentiment_score": "0.168324", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment", "url": "https://www.globenewswire.com/news-release/2024/09/12/2945176/0/en/Clearmind-Medicine-and-Yissum-File-International-Patent-Application-for-Revolutionary-Psychedelic-Compounds-for-PTSD-Treatment.html", "time_published": "20240912T122000", "authors": ["Clearmind Medicine Inc."], "summary": "Innovative compounds designed to address critical unmet needs in PTSD treatment ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/52c0fa73-1317-4a42-bfa5-ea0252669a70", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.17405, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.160633", "ticker_sentiment_score": "0.156306", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment", "url": "https://www.globenewswire.com/news-release/2024/09/06/2942115/0/en/SciSparc-Clearmind-Medicine-Collaboration-Leads-to-Publication-of-International-Patent-Application-for-Innovative-MDMA-Based-Combination-Treatment.html", "time_published": "20240906T115500", "authors": ["SciSparc Ltd"], "summary": "Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.249344, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.447091", "ticker_sentiment_score": "0.30157", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.208017", "ticker_sentiment_score": "0.129272", "ticker_sentiment_label": "Neutral"}]}, {"title": "SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/09/g40747684/scisparc-clearmind-medicine-collaboration-leads-to-publication-of-international-patent-application", "time_published": "20240906T115500", "authors": ["Globe Newswire"], "summary": "Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 ( GLOBE NEWSWIRE ) -- SciSparc Ltd.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.256087, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.42944", "ticker_sentiment_score": "0.291306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.199037", "ticker_sentiment_score": "0.120136", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment", "url": "https://www.globenewswire.com/news-release/2024/09/06/2942116/0/en/Clearmind-Medicine-Announces-Publication-of-International-Patent-Application-for-Innovative-MDMA-Based-Combination-Treatment.html", "time_published": "20240906T115500", "authors": ["Clearmind Medicine Inc."], "summary": "Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacyin Mental Health and Addiction Treatments ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/52c0fa73-1317-4a42-bfa5-ea0252669a70", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.15868, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.206862", "ticker_sentiment_score": "0.125578", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.166169", "ticker_sentiment_score": "0.139342", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/09/g40747685/clearmind-medicine-announces-publication-of-international-patent-application-for-innovative-mdma-b", "time_published": "20240906T115500", "authors": ["Globe Newswire"], "summary": "Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments Vancouver, Canada, Sept. 06, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc.", "banner_image": "https://ml.globenewswire.com/media/52c0fa73-1317-4a42-bfa5-ea0252669a70/small/clearmindnewlogo-png.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.167908, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.199694", "ticker_sentiment_score": "0.120633", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.160365", "ticker_sentiment_score": "0.129142", "ticker_sentiment_label": "Neutral"}]}, {"title": "SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination", "url": "https://www.globenewswire.com/news-release/2024/08/29/2938125/0/en/SciSparc-Clearmind-Medicine-Collaboration-Leads-to-Publication-of-Application-for-Innovative-Ketamine-Based-Combination.html", "time_published": "20240829T202500", "authors": ["SciSparc Ltd"], "summary": "TEL AVIV, Israel, Aug. 29, 2024 ( GLOBE NEWSWIRE ) -- SciSparc Ltd. ( Nasdaq: SPRC ) ( \"Company\" or \"SciSparc\" ) , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.031359, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MFCSF", "relevance_score": "0.053992", "ticker_sentiment_score": "-0.008998", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRC", "relevance_score": "0.501722", "ticker_sentiment_score": "0.152367", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.16099", "ticker_sentiment_score": "0.102571", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment", "url": "https://www.globenewswire.com/news-release/2024/08/29/2938124/0/en/Clearmind-Medicine-Announces-Publication-of-its-Patent-Application-for-Innovative-Ketamine-Based-Combination-Treatment.html", "time_published": "20240829T202500", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, Aug. 29, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/52c0fa73-1317-4a42-bfa5-ea0252669a70", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.079453, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MFCSF", "relevance_score": "0.037329", "ticker_sentiment_score": "-0.008736", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRC", "relevance_score": "0.291904", "ticker_sentiment_score": "0.098049", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.11166", "ticker_sentiment_score": "0.115382", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment", "url": "https://www.globenewswire.com/news-release/2024/08/21/2933847/0/en/Clearmind-Medicine-Granted-U-S-Patent-Approval-for-Binge-Behavior-Treatment.html", "time_published": "20240821T201100", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, Aug. 21, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/52c0fa73-1317-4a42-bfa5-ea0252669a70", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.110083, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.137148", "ticker_sentiment_score": "0.147045", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders", "url": "https://www.globenewswire.com/news-release/2024/08/16/2931717/0/en/Clearmind-Medicine-and-Yissum-Expand-Collaboration-with-International-Patent-Application-for-Generation-3-0-Psychedelic-Compounds-to-Treat-Mental-Disorders.html", "time_published": "20240816T201400", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, Aug. 16, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/52c0fa73-1317-4a42-bfa5-ea0252669a70", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.209116, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LEIC", "relevance_score": "0.042271", "ticker_sentiment_score": "0.039638", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.126339", "ticker_sentiment_score": "0.110497", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Doximity  ( NYSE:DOCS ) ", "url": "https://www.benzinga.com/news/24/08/40277872/why-doximity-shares-are-trading-higher-by-over-28-here-are-20-stocks-moving-premarket", "time_published": "20240809T090452", "authors": ["Avi Kapoor"], "summary": "Shares of Doximity, Inc. DOCS rose sharply in today's pre-market trading reported better-than-expected first-quarter financial results and issued strong FY24 revenue guidance. Doximity's first-quarter revenue increased 17% year-over-year to $126.68 million, beating the consensus estimate of ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/09/wall-street-ai16.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.865346"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.192669, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RDDT", "relevance_score": "0.07157", "ticker_sentiment_score": "0.106634", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUGE", "relevance_score": "0.142565", "ticker_sentiment_score": "0.38156", "ticker_sentiment_label": "Bullish"}, {"ticker": "WENA", "relevance_score": "0.142565", "ticker_sentiment_score": "0.135966", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRIN", "relevance_score": "0.142565", "ticker_sentiment_score": "0.130674", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVD", "relevance_score": "0.142565", "ticker_sentiment_score": "0.141832", "ticker_sentiment_label": "Neutral"}, {"ticker": "CUTR", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.038829", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRVN", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.232315", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IOVA", "relevance_score": "0.142565", "ticker_sentiment_score": "0.346489", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SG", "relevance_score": "0.142565", "ticker_sentiment_score": "0.247149", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BW", "relevance_score": "0.142565", "ticker_sentiment_score": "0.302546", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PUBM", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.049882", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOTE", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.061422", "ticker_sentiment_label": "Neutral"}, {"ticker": "POWW", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.219787", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DOCS", "relevance_score": "0.212425", "ticker_sentiment_score": "0.475184", "ticker_sentiment_label": "Bullish"}, {"ticker": "FIVN", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.217463", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EB", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.046245", "ticker_sentiment_label": "Neutral"}, {"ticker": "KITT", "relevance_score": "0.212425", "ticker_sentiment_score": "0.312683", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NRDY", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.19516", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AVGR", "relevance_score": "0.142565", "ticker_sentiment_score": "0.17904", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.142565", "ticker_sentiment_score": "0.11776", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITI", "relevance_score": "0.142565", "ticker_sentiment_score": "0.112088", "ticker_sentiment_label": "Neutral"}]}, {"title": "SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug", "url": "https://www.globenewswire.com/news-release/2024/08/06/2925081/0/en/SciSparc-s-Collaboration-with-Clearmind-Medicine-Continues-to-Bear-Fruit-With-New-Scientific-Article-Showing-MEAI-Potential-as-a-Novel-Weight-Loss-Drug.html", "time_published": "20240806T125700", "authors": ["SciSparc Ltd"], "summary": "SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc's Palmitoylethanolamide ( PEA ) with ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.139061, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.432291", "ticker_sentiment_score": "0.175971", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.224903", "ticker_sentiment_score": "0.1773", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug", "url": "https://www.globenewswire.com/news-release/2024/08/06/2925083/0/en/Clearmind-Medicine-New-Scientific-Publication-Shows-MEAI-s-Potential-as-a-Novel-Weight-Loss-Drug.html", "time_published": "20240806T125700", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, Aug. 06, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/94cfe932-610a-4cd2-98a5-9e0699313ea1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.082091, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.17715", "ticker_sentiment_score": "0.053143", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine - Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research", "url": "https://www.globenewswire.com/news-release/2024/07/31/2921785/0/en/Clearmind-Medicine-Concludes-the-Successful-Participation-in-the-Psychedelic-Medicine-Israel-2024-Conference-Presented-Industry-Leaders-its-Groundbreaking-Research.html", "time_published": "20240731T114400", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, July 31, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/94cfe932-610a-4cd2-98a5-9e0699313ea1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.233365, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.152258", "ticker_sentiment_score": "0.267629", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product", "url": "https://www.globenewswire.com/news-release/2024/07/19/2915832/0/en/Clearmind-Medicine-Signs-an-Agreement-to-Source-Manufacturers-and-Distributors-for-its-Alcohol-Substitute-Beverage-Product.html", "time_published": "20240719T115500", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, July 19, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/94cfe932-610a-4cd2-98a5-9e0699313ea1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.208603, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.190793", "ticker_sentiment_score": "0.2561", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nasdaq Edges Lower; Morgan Stanley Earnings Top Views - Morgan Stanley  ( NYSE:MS ) ", "url": "https://www.benzinga.com/news/earnings/24/07/39802034/nasdaq-edges-lower-morgan-stanley-earnings-top-views", "time_published": "20240716T183151", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index surging more than 650 points on Tuesday. The Dow traded up 1.63% to 40,865.59 while the NASDAQ fell 0.11% to 18,452.31. The S&P 500 also rose, gaining, 0.37% to 5,652.28. Industrials shares jumped by 2.3% on ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/16/Image32.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Finance", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.065552, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SCHW", "relevance_score": "0.14131", "ticker_sentiment_score": "0.190513", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RDDT", "relevance_score": "0.14131", "ticker_sentiment_score": "0.148544", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.070935", "ticker_sentiment_score": "-0.13076", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.210579", "ticker_sentiment_score": "-0.06784", "ticker_sentiment_label": "Neutral"}, {"ticker": "TKLF", "relevance_score": "0.14131", "ticker_sentiment_score": "0.337647", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.278222", "ticker_sentiment_score": "-0.148707", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crude Oil Down 1%; Bank of America Posts Upbeat Earnings - Bank of America  ( NYSE:BAC ) ", "url": "https://www.benzinga.com/news/earnings/24/07/39799013/crude-oil-down-1-bank-of-america-posts-upbeat-earnings", "time_published": "20240716T160052", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded mostly higher midway through trading, with the Dow Jones index surging more than 550 points on Tuesday. The Dow traded up 1.41% to 40,779.92 while the NASDAQ fell 0.05% to 18,463.13. The S&P 500 also rose, gaining, 0.35% to 5,651.05. Industrials shares jumped by 2% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/16/wall-street-chart-shutter2.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Finance", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.092176, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SCHW", "relevance_score": "0.140485", "ticker_sentiment_score": "0.189908", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.140485", "ticker_sentiment_score": "0.534569", "ticker_sentiment_label": "Bullish"}, {"ticker": "RDDT", "relevance_score": "0.140485", "ticker_sentiment_score": "0.148068", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.070517", "ticker_sentiment_score": "-0.130708", "ticker_sentiment_label": "Neutral"}, {"ticker": "TKLF", "relevance_score": "0.140485", "ticker_sentiment_score": "0.336636", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.276648", "ticker_sentiment_score": "-0.14803", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jumps 400 Points; US Retail Sales Flat For June - Autonomix Medical  ( NASDAQ:AMIX ) ", "url": "https://www.benzinga.com/news/earnings/24/07/39795907/dow-jumps-400-points-us-retail-sales-flat-for-june", "time_published": "20240716T140430", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher this morning, with the Dow Jones index rising more than 400 points on Tuesday. Following the market opening Tuesday, the Dow traded up 1% to 40,614.31 while the NASDAQ rose 0.14% to 18,498.00. The S&P 500 also rose, gaining, 0.33% to 5,649.84.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/16/Image33.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.108674, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CYN", "relevance_score": "0.169676", "ticker_sentiment_score": "0.199197", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMIX", "relevance_score": "0.169676", "ticker_sentiment_score": "0.371829", "ticker_sentiment_label": "Bullish"}, {"ticker": "TKLF", "relevance_score": "0.169676", "ticker_sentiment_score": "0.374456", "ticker_sentiment_label": "Bullish"}, {"ticker": "CMND", "relevance_score": "0.331765", "ticker_sentiment_score": "-0.170847", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism", "url": "https://www.globenewswire.com/news-release/2024/07/16/2913847/0/en/Clearmind-Medicine-Obtains-IND-Approval-from-the-FDA-to-Start-the-Phase-I-IIa-Clinical-Trial-with-its-Innovative-Treatment-for-Alcoholism.html", "time_published": "20240716T130200", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, July 16, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/94cfe932-610a-4cd2-98a5-9e0699313ea1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.200961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.429238", "ticker_sentiment_score": "0.233975", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss", "url": "https://www.globenewswire.com/news-release/2024/07/16/2913567/0/en/Clearmind-Medicine-Announces-Submission-of-US-Patent-Application-for-Treating-Metabolic-Syndrome-and-Weight-loss.html", "time_published": "20240716T100300", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, July 16, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/94cfe932-610a-4cd2-98a5-9e0699313ea1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.085914, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.184246", "ticker_sentiment_score": "0.051456", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.13873", "ticker_sentiment_score": "0.116884", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine - Israel 2024 Conference", "url": "https://www.globenewswire.com/news-release/2024/07/12/2912367/0/en/Clearmind-Medicine-to-Present-Groundbreaking-Research-at-Psychedelic-Medicine-Israel-2024-Conference.html", "time_published": "20240712T120200", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, July 12, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/94cfe932-610a-4cd2-98a5-9e0699313ea1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.1602, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.162255", "ticker_sentiment_score": "0.174089", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/24/06/39554543/why-psychedelic-pharma-clearmind-medicine-stock-is-moving-higher", "time_published": "20240628T171140", "authors": ["Erica Kollmann"], "summary": "Clearmind Medicine Inc. CMND shares are trading higher Friday after the company announced advancement in its proprietary MEAI-based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/28/financial-psychedelics-Raimundo79-and-Bl.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Finance", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}], "overall_sentiment_score": 0.297776, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BRK-A", "relevance_score": "0.081552", "ticker_sentiment_score": "0.171544", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.461006", "ticker_sentiment_score": "0.402611", "ticker_sentiment_label": "Bullish"}]}, {"title": "Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment", "url": "https://www.globenewswire.com/news-release/2024/06/28/2905795/0/en/Clearmind-Medicine-Granted-Patent-Approval-in-Hong-Kong-for-its-Binge-Behaviors-Treatment.html", "time_published": "20240628T115500", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, June 28, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/a7ea5023-f815-411c-bec6-7f78ceb35e2a", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.067508, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.159569", "ticker_sentiment_score": "0.136675", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/06/g39546173/clearmind-medicine-granted-patent-approval-in-hong-kong-for-its-binge-behaviors-treatment", "time_published": "20240628T115500", "authors": ["Globe Newswire"], "summary": "Vancouver, Canada, June 28, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.084224, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.152178", "ticker_sentiment_score": "0.125712", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment", "url": "https://www.globenewswire.com/news-release/2024/06/20/2901607/0/en/Clearmind-Medicine-Secured-Exclusive-Global-Rights-to-Innovative-Psychedelic-Compounds-for-PTSD-Treatment.html", "time_published": "20240620T115700", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, June 20, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/a7ea5023-f815-411c-bec6-7f78ceb35e2a", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.166291, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.140348", "ticker_sentiment_score": "0.134522", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going On With Clearmind Medicine Stock Tuesday? - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/24/06/39275472/whats-going-on-with-clearmind-medicine-stock-tuesday", "time_published": "20240611T163934", "authors": ["Adam Eckert"], "summary": "Clearmind Medicine Inc CMND on Tuesday announced advancement in its proprietary MEAI-based alcohol substitute beverage program. What Happened: Clearmind previously announced the initiation of the last pre-clinical study required for a novel-food application submission.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/11/stock-chart-1863880-1920-60.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.995077"}], "overall_sentiment_score": 0.244689, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.313484", "ticker_sentiment_score": "0.139495", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink", "url": "https://www.globenewswire.com/news-release/2024/06/11/2896691/0/en/Clearmind-Medicine-Revolutionizes-the-13-Billion-NonAlcoholic-Beverages-Market-with-its-Psychedelic-Based-Drink.html", "time_published": "20240611T114400", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, June 11, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/19773564-50ba-496f-82c9-af36cfa887b7", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.118607, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.168884", "ticker_sentiment_score": "0.075751", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/06/g39267718/clearmind-medicine-revolutionizes-the-13-billion-nonalcoholic-beverages-market-with-its-psychedeli", "time_published": "20240611T114400", "authors": ["Globe Newswire"], "summary": "Vancouver, Canada, June 11, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. CMND, CWY ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.13266, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.159922", "ticker_sentiment_score": "0.067294", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product", "url": "https://www.globenewswire.com/news-release/2024/05/10/2879598/0/en/Clearmind-Medicine-Advances-its-Proprietary-Psychedelic-Based-Synthetic-Alcohol-Beverage-Product.html", "time_published": "20240510T122400", "authors": ["Clearmind Medicine Inc."], "summary": "The global market of no- and low-alcohol beverages estimated at over $13 billion in ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/19773564-50ba-496f-82c9-af36cfa887b7", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.181219, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.142005", "ticker_sentiment_score": "0.067787", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/05/g38758890/clearmind-medicine-advances-its-proprietary-psychedelic-based-synthetic-alcohol-beverage-product", "time_published": "20240510T122400", "authors": ["Globe Newswire"], "summary": "The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.188111, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.135602", "ticker_sentiment_score": "0.060877", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Clearmind Medicine Stock Is Moving Higher - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/24/05/38673181/why-clearmind-medicine-stock-is-moving-higher", "time_published": "20240507T150321", "authors": ["Dylan Berman"], "summary": "Clearmind Medicine Inc. CMND shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/07/movers-image_12.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.531459, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.682689", "ticker_sentiment_score": "0.820927", "ticker_sentiment_label": "Bullish"}]}, {"title": "Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment", "url": "https://www.globenewswire.com/news-release/2024/05/07/2876629/0/en/Clearmind-Medicine-Secures-Exclusive-Global-Rights-to-Breakthrough-Psychedelic-Compounds-for-PTSD-Treatment.html", "time_published": "20240507T114600", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, May 07, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"Company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/19773564-50ba-496f-82c9-af36cfa887b7", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.246902, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.122477", "ticker_sentiment_score": "0.126516", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/05/g38665765/clearmind-medicine-secures-exclusive-global-rights-to-breakthrough-psychedelic-compounds-for-ptsd-", "time_published": "20240507T114600", "authors": ["Globe Newswire"], "summary": "Vancouver, Canada, May 07, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.249016, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.117486", "ticker_sentiment_score": "0.118108", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Applies to Cease Being a Reporting Issuer in Canada", "url": "https://www.globenewswire.com/news-release/2024/04/30/2872793/0/en/Clearmind-Applies-to-Cease-Being-a-Reporting-Issuer-in-Canada.html", "time_published": "20240430T201500", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, April 30, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWYO ) ( \"Clearmind\" or the \"Company\" ) , a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/19773564-50ba-496f-82c9-af36cfa887b7", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.988787"}], "overall_sentiment_score": 0.12786, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.152821", "ticker_sentiment_score": "0.182148", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders", "url": "https://www.globenewswire.com/news-release/2024/04/17/2864428/0/en/Clearmind-Medicine-Announces-Exclusive-Licensing-Agreement-for-Generation-3-0-Psychedelic-Compounds-for-the-Treatment-of-Mental-Disorders.html", "time_published": "20240417T114900", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.274982, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.140348", "ticker_sentiment_score": "0.136673", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders", "url": "https://www.globenewswire.com/news-release/2024/04/10/2860639/0/en/Clearmind-Medicine-Files-U-S-Patent-Application-for-Psychedelic-Based-Treatment-for-Eating-Disorders.html", "time_published": "20240410T111700", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, April 10, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"company\" ) , a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.043418, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.16317", "ticker_sentiment_score": "0.133783", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/04/g38179532/clearmind-medicine-files-u-s-patent-application-for-psychedelic-based-treatment-for-eating-disorde", "time_published": "20240410T111700", "authors": ["Globe Newswire"], "summary": "Vancouver, Canada, April 10, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.057747, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.153145", "ticker_sentiment_score": "0.105304", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine CEO Issues Letter to Shareholders", "url": "https://www.globenewswire.com/news-release/2024/04/09/2859968/0/en/Clearmind-Medicine-CEO-Issues-Letter-to-Shareholders.html", "time_published": "20240409T120700", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, April 09, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq:CMND ) , ( FSE: CWY0 ) ( \"Clearmind\" or the \"company\" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.203048, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.294977", "ticker_sentiment_score": "0.18736", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression", "url": "https://www.globenewswire.com/news-release/2024/03/27/2853253/0/en/Clearmind-Medicine-Announces-International-Patent-Application-for-Preventing-and-Treating-Depression.html", "time_published": "20240327T131200", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, March 27, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.021771, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.179121", "ticker_sentiment_score": "0.022897", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.134841", "ticker_sentiment_score": "0.073645", "ticker_sentiment_label": "Neutral"}]}, {"title": "SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression", "url": "https://www.globenewswire.com/news-release/2024/03/27/2853200/0/en/SciSparc-Clearmind-Collaboration-Evolves-with-New-International-Patent-Application-for-Preventing-and-Treating-Depression.html", "time_published": "20240327T125500", "authors": ["SciSparc Ltd"], "summary": "TEL AVIV, Israel, March 27, 2024 ( GLOBE NEWSWIRE ) -- SciSparc Ltd. ( Nasdaq: SPRC ) ( \"Company\" or \"SciSparc\" ) , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": -0.012038, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.459624", "ticker_sentiment_score": "0.033489", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.20698", "ticker_sentiment_score": "0.083951", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket - BYND Cannasoft Enterprise  ( NASDAQ:BCAN ) , Aquestive Therapeutics  ( NASDAQ:AQST ) ", "url": "https://www.benzinga.com/news/24/03/37844820/why-taysha-gene-therapies-shares-are-trading-higher-by-around-27-here-are-20-stocks-moving-premarket", "time_published": "20240320T122039", "authors": ["Avi Kapoor"], "summary": "Shares of Taysha Gene Therapies, Inc. TSHA rose sharply in today's pre-market trading after the company reported a year-over-year increase in FY23 EPS results. The company reported fiscal year 2023 losses of 96 cents per share, compared to losses of $3.78 per share from the prior year.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/20/image19.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.897321"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.162621, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CERO", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.217199", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "META", "relevance_score": "0.062434", "ticker_sentiment_score": "-0.033042", "ticker_sentiment_label": "Neutral"}, {"ticker": "GETY", "relevance_score": "0.185781", "ticker_sentiment_score": "0.431629", "ticker_sentiment_label": "Bullish"}, {"ticker": "MGRX", "relevance_score": "0.124486", "ticker_sentiment_score": "0.30415", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MNTS", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.026876", "ticker_sentiment_label": "Neutral"}, {"ticker": "OBLG", "relevance_score": "0.124486", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOPA", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.076199", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQST", "relevance_score": "0.185781", "ticker_sentiment_score": "0.075299", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCAN", "relevance_score": "0.185781", "ticker_sentiment_score": "-0.078884", "ticker_sentiment_label": "Neutral"}, {"ticker": "HROW", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.217199", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WFC", "relevance_score": "0.062434", "ticker_sentiment_score": "-0.003029", "ticker_sentiment_label": "Neutral"}, {"ticker": "WORX", "relevance_score": "0.124486", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERB", "relevance_score": "0.124486", "ticker_sentiment_score": "-0.038483", "ticker_sentiment_label": "Neutral"}, {"ticker": "MXCT", "relevance_score": "0.185781", "ticker_sentiment_score": "0.371462", "ticker_sentiment_label": "Bullish"}, {"ticker": "SMR", "relevance_score": "0.185781", "ticker_sentiment_score": "-0.004715", "ticker_sentiment_label": "Neutral"}, {"ticker": "EZFL", "relevance_score": "0.124486", "ticker_sentiment_score": "0.074199", "ticker_sentiment_label": "Neutral"}, {"ticker": "OTRK", "relevance_score": "0.124486", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETAO", "relevance_score": "0.124486", "ticker_sentiment_score": "0.013366", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGC", "relevance_score": "0.124486", "ticker_sentiment_score": "0.145204", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.185781", "ticker_sentiment_score": "0.310014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FUFU", "relevance_score": "0.124486", "ticker_sentiment_score": "0.446928", "ticker_sentiment_label": "Bullish"}, {"ticker": "TSHA", "relevance_score": "0.185781", "ticker_sentiment_score": "0.205439", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China", "url": "https://www.globenewswire.com/news-release/2024/03/19/2848474/0/en/Breakthrough-in-Wellness-Clearmind-Medicine-s-Psychedelic-Treatment-Granted-Divisional-Patent-Approval-in-China.html", "time_published": "20240319T115500", "authors": ["Clearmind Medicine Inc."], "summary": "A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic Therapy ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.173166, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.125898", "ticker_sentiment_score": "0.193994", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/03/g37818648/breakthrough-in-wellness-clearmind-medicines-psychedelic-treatment-granted-divisional-patent-appro", "time_published": "20240319T115500", "authors": ["Globe Newswire"], "summary": "A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic Therapy Tel Aviv, Israel / Vancouver, Canada, March 19, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.177718, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.120834", "ticker_sentiment_score": "0.180836", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial", "url": "https://www.globenewswire.com/news-release/2024/03/13/2845404/0/en/Clearmind-Medicine-Obtains-Clearance-for-its-Psychedelic-Based-Alcoholism-Clinical-Trial.html", "time_published": "20240313T121400", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, March 13, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.213359, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.381172", "ticker_sentiment_score": "0.352593", "ticker_sentiment_label": "Bullish"}]}, {"title": "Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange", "url": "https://www.globenewswire.com/news-release/2024/03/13/2845324/0/en/Clearmind-Medicine-Received-Approval-for-a-Voluntary-Delisting-of-its-Common-Shares-From-the-Canadian-Securities-Exchange.html", "time_published": "20240313T113000", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, March 13, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.980716"}], "overall_sentiment_score": 0.186086, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.211191", "ticker_sentiment_score": "0.22374", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/02/g37332889/clearmind-medicine-submits-three-additional-international-patent-applications-for-innovative-mdma-", "time_published": "20240227T125800", "authors": ["Globe Newswire"], "summary": "New patent applications build upon Clearmind's broad IP protection in the psychedelic space", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.076255, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.147216", "ticker_sentiment_score": "0.058236", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.098456", "ticker_sentiment_score": "0.075182", "ticker_sentiment_label": "Neutral"}]}, {"title": "SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/02/g37332890/scisparc-clearmind-partnership-yields-three-new-international-patent-applications-for-mdma-ibogain", "time_published": "20240227T125800", "authors": ["Globe Newswire"], "summary": "TEL AVIV, Israel, Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- SciSparc Ltd.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.035768, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.480536", "ticker_sentiment_score": "0.056082", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.217508", "ticker_sentiment_score": "0.083701", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds", "url": "https://www.globenewswire.com/news-release/2024/02/27/2835920/0/en/Clearmind-Medicine-Submits-Three-Additional-International-Patent-Applications-for-Innovative-MDMA-Ibogaine-and-Ketamine-Compounds.html", "time_published": "20240227T125800", "authors": ["Clearmind Medicine Inc."], "summary": "New patent applications build upon Clearmind's broad IP protection in the psychedelic space ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.078788, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.150278", "ticker_sentiment_score": "0.06582", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.150278", "ticker_sentiment_score": "0.097932", "ticker_sentiment_label": "Neutral"}]}, {"title": "EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/general/biotech/24/02/37332186/exclusive-psychedelic-focused-firm-clearmind-medicine-submits-three-new-international-patent-appl", "time_published": "20240227T123037", "authors": ["Vandana Singh"], "summary": "On Tuesday, Clearmind Medicine Inc CMND submitted three additional patent applications under the international Patent Cooperation Treaty ( PCT ) as part of its ongoing collaboration with SciSparc Ltd SPRC.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/psychedelic-chemistry-geralt-by-pixabay_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.106891, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.331765", "ticker_sentiment_score": "0.158772", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.524949", "ticker_sentiment_score": "0.022961", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder", "url": "https://www.globenewswire.com/news-release/2024/02/23/2834392/0/en/Clearmind-Medicine-Receives-Approval-to-Commence-its-Phase-I-IIa-Clinical-Trial-of-CMND-100-for-Alcohol-Use-Disorder.html", "time_published": "20240223T120600", "authors": ["Clearmind Medicine Inc."], "summary": "For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.218439, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.380591", "ticker_sentiment_score": "0.377994", "ticker_sentiment_label": "Bullish"}]}, {"title": "Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/24/02/37239879/next-gen-psychedelics-companies-scisparc-and-clearmind-collaboration-file-3-patents", "time_published": "20240221T161239", "authors": ["Patricio Liddle"], "summary": "The ongoing collaboration between SciSparc Ltd. SPRC and Clearmind Medicine Inc. CMND CMND CWY resulted in the Tuesday filing of three patent applications under the International Patent Cooperation Treaty.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/psychpatents.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.355068, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.340915", "ticker_sentiment_score": "0.128904", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.259267", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock? - SciSparc  ( NASDAQ:SPRC ) ", "url": "https://www.benzinga.com/markets/cannabis/24/02/37219436/whats-going-on-with-psychedelic-drug-developers-scisparc-and-clearmind-stock", "time_published": "20240220T182921", "authors": ["Erica Kollmann"], "summary": "SciSparc Ltd. SPRC and Clearmind Medicine Inc. CMND shares are trading higher Tuesday after the companies announced the submission of three international patent applications as part of the ongoing collaboration between the companies.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/fractal-1680252-1280.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}], "overall_sentiment_score": 0.328672, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.542539", "ticker_sentiment_score": "0.401276", "ticker_sentiment_label": "Bullish"}, {"ticker": "BRK-A", "relevance_score": "0.074001", "ticker_sentiment_score": "0.16933", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.219477", "ticker_sentiment_score": "0.226871", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds", "url": "https://www.globenewswire.com/news-release/2024/02/20/2831697/0/en/SciSparc-and-Clearmind-Continue-to-Strengthen-International-Patent-Portfolio-with-Next-Generation-Classic-Psychedelic-Based-Compounds.html", "time_published": "20240220T121400", "authors": ["SciSparc Ltd"], "summary": "TEL AVIV, Israel, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- SciSparc Ltd. ( Nasdaq: SPRC ) ( \"Company\" or \"SciSparc\" ) , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.10934, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.470482", "ticker_sentiment_score": "0.067555", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.212425", "ticker_sentiment_score": "0.089054", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds", "url": "https://www.globenewswire.com/news-release/2024/02/20/2831696/0/en/Clearmind-Medicine-Submits-Three-International-Patent-Applications-for-Next-Generation-Classic-Psychedelic-Based-Compounds.html", "time_published": "20240220T121400", "authors": ["Clearmind Medicine Inc."], "summary": "Vancouver, Canada, Feb. 20, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.128377, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.243864", "ticker_sentiment_score": "0.165943", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.147818", "ticker_sentiment_score": "0.096952", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China", "url": "https://www.globenewswire.com/news-release/2024/02/05/2823448/0/en/Clearmind-Medicine-Receives-Patent-Approval-for-its-Psychedelic-Based-Treatment-of-Binge-Behaviors-in-China.html", "time_published": "20240205T125100", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, Feb. 05, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.143157, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.142284", "ticker_sentiment_score": "0.217665", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/02/g36887068/clearmind-medicine-announces-exclusive-long-term-licensing-agreement-with-leading-israeli-research", "time_published": "20240201T131500", "authors": ["Globe Newswire"], "summary": "The licensing agreement refers to the company's dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.171648, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NHPEF", "relevance_score": "0.072", "ticker_sentiment_score": "0.065006", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.072", "ticker_sentiment_score": "0.135486", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center", "url": "https://www.globenewswire.com/news-release/2024/02/01/2821963/0/en/Clearmind-Medicine-Announces-Exclusive-Long-Term-Licensing-Agreement-with-Leading-Israeli-Research-Center.html", "time_published": "20240201T131500", "authors": ["Clearmind Medicine Inc."], "summary": "The licensing agreement refers to the company's dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.178734, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NHPEF", "relevance_score": "0.073209", "ticker_sentiment_score": "0.064122", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.109622", "ticker_sentiment_score": "0.157695", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More - ATAI Life Sciences  ( NASDAQ:ATAI ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/24/01/36814962/psyched-suggestibility-and-psychedelics-effects-eus-7m-research-fund-australias-treatment-delive", "time_published": "20240127T150018", "authors": ["Lara Goldstein"], "summary": "A new study led by Bal\u00e1zs Szigeti and with involvement of researchers Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt and Robin Carhart-Harris found evidence of suggestibility predicting an antidepressant response for patients receiving psilocybin therapy.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.071122, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRUG", "relevance_score": "0.09239", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IXHL", "relevance_score": "0.183546", "ticker_sentiment_score": "0.18278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMPS", "relevance_score": "0.138198", "ticker_sentiment_score": "-0.062971", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVB", "relevance_score": "0.09239", "ticker_sentiment_score": "-0.114703", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNMD", "relevance_score": "0.138198", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.09239", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.09239", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SILO", "relevance_score": "0.09239", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36645025/clearmind-medicine-inc-closes-us-2-4-million-registered-direct-and-private-placement", "time_published": "20240116T161934", "authors": ["Globe Newswire"], "summary": "TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "IPO", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.983783"}], "overall_sentiment_score": 0.147942, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.112709", "ticker_sentiment_score": "0.093665", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement", "url": "https://www.globenewswire.com/news-release/2024/01/16/2810139/0/en/Clearmind-Medicine-Inc-Closes-US-2-4-Million-Registered-Direct-and-Private-Placement.html", "time_published": "20240116T161900", "authors": ["Clearmind Medicine Inc."], "summary": "TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( NASDAQ: CMND ) ( the \"Company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "IPO", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.967321"}], "overall_sentiment_score": 0.150268, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.109123", "ticker_sentiment_score": "0.095949", "ticker_sentiment_label": "Neutral"}]}, {"title": "Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More - ATAI Life Sciences  ( NASDAQ:ATAI ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/24/01/36623584/psychedelics-headlines-mdma-coping-skills-in-ptsd-lsds-perceived-risks-knowledge-gaps-surveys-mo", "time_published": "20240115T183832", "authors": ["Lara Goldstein"], "summary": "Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024. See previous edition: Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/13/psyched_new_-_option_1.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.097448, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMPS", "relevance_score": "0.093047", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.06211", "ticker_sentiment_score": "-0.112032", "ticker_sentiment_label": "Neutral"}, {"ticker": "GBNH", "relevance_score": "0.031079", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.06211", "ticker_sentiment_score": "-0.207189", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More - ATAI Life Sciences  ( NASDAQ:ATAI ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/24/01/36618728/psyched-100m-for-mdma-therapy-va-funds-2024-watchlist-reform-updates-and-more", "time_published": "20240112T215540", "authors": ["Lara Goldstein"], "summary": "A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies ( MAPS ) , MAPS Public Benefit Corporation has secured over $100 million in a Series A private stock sale.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/12/psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.192357, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DRUG", "relevance_score": "0.095899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IXHL", "relevance_score": "0.095899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPS", "relevance_score": "0.095899", "ticker_sentiment_score": "-0.115703", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVB", "relevance_score": "0.095899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNMD", "relevance_score": "0.143415", "ticker_sentiment_score": "-0.109978", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.095899", "ticker_sentiment_score": "-0.131577", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.095899", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SILO", "relevance_score": "0.095899", "ticker_sentiment_score": "0.136873", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crude Oil Moves Higher; Clearmind Medicine Shares Plummet - First Financial Northwest  ( NASDAQ:FFNW ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/earnings/24/01/36600288/crude-oil-moves-higher-clearmind-medicine-shares-plummet", "time_published": "20240111T193251", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded slightly lower toward the end of trading, with the Dow Jones index falling around 20 points on Thursday. The Dow traded down 0.05% to 37,675 while the NASDAQ fell 0.05% to 14,962.80. The S&P 500 also fell, dropping, 0.11% to 4,778.06. In trading on Thursday, utilities shares ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/11/image24.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": -0.02671, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LAES", "relevance_score": "0.217508", "ticker_sentiment_score": "0.51377", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.073321", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNECF", "relevance_score": "0.073321", "ticker_sentiment_score": "0.257905", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RELL", "relevance_score": "0.146025", "ticker_sentiment_score": "0.136233", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGAN", "relevance_score": "0.146025", "ticker_sentiment_score": "0.318849", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FFNW", "relevance_score": "0.217508", "ticker_sentiment_score": "0.303928", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OPI", "relevance_score": "0.146025", "ticker_sentiment_score": "0.037906", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.217508", "ticker_sentiment_score": "0.189447", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dow Dips Over 200 Points; First Financial Northwest Shares Spike Higher - First Financial Northwest  ( NASDAQ:FFNW ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/earnings/24/01/36598234/dow-dips-over-200-points-first-financial-northwest-shares-spike-higher", "time_published": "20240111T171136", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 200 points on Thursday. The Dow traded down 0.56% to 37,483.91 while the NASDAQ fell 0.86% to 14,840.28. The S&P 500 also fell, dropping, 0.70% to 4,749.93. In trading on Thursday, utilities shares fell by 1.9%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/11/image39.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.002436, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LAES", "relevance_score": "0.220809", "ticker_sentiment_score": "0.518611", "ticker_sentiment_label": "Bullish"}, {"ticker": "C", "relevance_score": "0.07446", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNECF", "relevance_score": "0.07446", "ticker_sentiment_score": "0.258298", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TGAN", "relevance_score": "0.148273", "ticker_sentiment_score": "0.321521", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FFNW", "relevance_score": "0.220809", "ticker_sentiment_score": "0.307327", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OPI", "relevance_score": "0.148273", "ticker_sentiment_score": "0.038263", "ticker_sentiment_label": "Neutral"}, {"ticker": "YGF", "relevance_score": "0.220809", "ticker_sentiment_score": "0.271945", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.220809", "ticker_sentiment_score": "0.191674", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Clearmind Medicine  ( CMND )  Shares Are Nosediving - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/24/01/36595516/why-clearmind-medicine-cmnd-shares-are-nosediving", "time_published": "20240111T154955", "authors": ["Henry Khederian"], "summary": "Clearmind Medicine Inc CMND shares are trading lower by 45% to $1.61 Thursday morning after the company finalized agreements with institutional investors for a registered direct offering. The offering includes the sale of 1.5 million Common Units, comprising Common Shares or Pre-Funded Warrants, ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/11/analysis-4937349.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.016733, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.693563", "ticker_sentiment_score": "0.152815", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US Stocks Higher; Inflation Rate Increases To 3.4% In December - 180 Life Sciences  ( NASDAQ:ATNF ) , Atreca  ( NASDAQ:BCEL ) ", "url": "https://www.benzinga.com/news/earnings/24/01/36594814/us-stocks-higher-inflation-rate-increases-to-3-4-in-december", "time_published": "20240111T144455", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.07% to 37,723.53 while the NASDAQ rose 0.46% to 15,039.09. The S&P 500 also rose, gaining, 0.21% to 4,793.32.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/11/image48.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.083476, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IMNM", "relevance_score": "0.07157", "ticker_sentiment_score": "0.047448", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.07157", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATNF", "relevance_score": "0.212425", "ticker_sentiment_score": "-0.137691", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCEL", "relevance_score": "0.212425", "ticker_sentiment_score": "0.077794", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLEC", "relevance_score": "0.142565", "ticker_sentiment_score": "0.432882", "ticker_sentiment_label": "Bullish"}, {"ticker": "YGF", "relevance_score": "0.212425", "ticker_sentiment_score": "0.27205", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPEC", "relevance_score": "0.212425", "ticker_sentiment_score": "0.415468", "ticker_sentiment_label": "Bullish"}, {"ticker": "CMND", "relevance_score": "0.212425", "ticker_sentiment_score": "0.186022", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement", "url": "https://www.globenewswire.com/news-release/2024/01/11/2808018/0/en/Clearmind-Medicine-Inc-Announces-Pricing-of-2-4-Million-Registered-Direct-and-Private-Placement.html", "time_published": "20240111T142800", "authors": ["Clearmind Medicine Inc."], "summary": "TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 11, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( NASDAQ: CMND ) ( the \"Company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "IPO", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.980509"}], "overall_sentiment_score": 0.15697, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.102158", "ticker_sentiment_score": "0.092626", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket - 180 Life Sciences  ( NASDAQ:ATNF ) , Atreca  ( NASDAQ:BCEL ) ", "url": "https://www.benzinga.com/news/24/01/36591851/why-richardson-electronics-shares-are-trading-lower-by-13-here-are-20-stocks-moving-premarket", "time_published": "20240111T125127", "authors": ["Avi Kapoor"], "summary": "Shares of Richardson Electronics, Ltd. RELL fell sharply in today's pre-market trading after the company posted weaker-than-expected results for its second quarter. Richardson Electronics posted a quarterly loss of 13 cents per share, compared to market estimates for earnings of 1 cent per share.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/11/image21.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.882182"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.065465, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RDZN", "relevance_score": "0.208166", "ticker_sentiment_score": "-0.054097", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMNM", "relevance_score": "0.070105", "ticker_sentiment_score": "0.04534", "ticker_sentiment_label": "Neutral"}, {"ticker": "XCUR", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.229763", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RNECF", "relevance_score": "0.070105", "ticker_sentiment_score": "0.091395", "ticker_sentiment_label": "Neutral"}, {"ticker": "QLGN", "relevance_score": "0.139669", "ticker_sentiment_score": "0.074806", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGAN", "relevance_score": "0.139669", "ticker_sentiment_score": "0.110827", "ticker_sentiment_label": "Neutral"}, {"ticker": "SDIG", "relevance_score": "0.139669", "ticker_sentiment_score": "0.040968", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCTO", "relevance_score": "0.139669", "ticker_sentiment_score": "0.078996", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAVM", "relevance_score": "0.208166", "ticker_sentiment_score": "-0.036442", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAN", "relevance_score": "0.070105", "ticker_sentiment_score": "0.26705", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VYNE", "relevance_score": "0.208166", "ticker_sentiment_score": "-0.176815", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GBNH", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.05775", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATNF", "relevance_score": "0.208166", "ticker_sentiment_score": "-0.078294", "ticker_sentiment_label": "Neutral"}, {"ticker": "RELL", "relevance_score": "0.275091", "ticker_sentiment_score": "0.092972", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCEL", "relevance_score": "0.208166", "ticker_sentiment_score": "0.073244", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTM", "relevance_score": "0.139669", "ticker_sentiment_score": "0.224864", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BTCS", "relevance_score": "0.139669", "ticker_sentiment_score": "0.299315", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FTFT", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.204031", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SPEC", "relevance_score": "0.139669", "ticker_sentiment_score": "0.126955", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.208166", "ticker_sentiment_score": "-0.036487", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.275091", "ticker_sentiment_score": "0.41706", "ticker_sentiment_label": "Bullish"}]}, {"title": "Crude Oil Falls 1%; Amarin Shares Spike Higher - Aehr Test Systems  ( NASDAQ:AEHR ) , Aclaris Therapeutics  ( NASDAQ:ACRS ) ", "url": "https://www.benzinga.com/news/24/01/36582262/crude-oil-falls-1-amarin-shares-spike-higher", "time_published": "20240110T191625", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Wednesday. The Dow traded up 0.29% to 37,633.43 while the NASDAQ rose 0.72% to 14,965.31. The S&P 500 also rose, gaining, 0.48% to 4,779.31. Communication services shares rose by 1.1% on ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/10/crude_oil_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.026724, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AEHR", "relevance_score": "0.16117", "ticker_sentiment_score": "-0.087139", "ticker_sentiment_label": "Neutral"}, {"ticker": "DCGO", "relevance_score": "0.16117", "ticker_sentiment_score": "0.012585", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACRS", "relevance_score": "0.16117", "ticker_sentiment_score": "-0.029092", "ticker_sentiment_label": "Neutral"}, {"ticker": "KITT", "relevance_score": "0.239698", "ticker_sentiment_score": "0.474052", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMRN", "relevance_score": "0.16117", "ticker_sentiment_score": "0.246987", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.16117", "ticker_sentiment_score": "0.111389", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Gains 50 Points; US Crude Inventories Rise Last Week - Aehr Test Systems  ( NASDAQ:AEHR ) , Aclaris Therapeutics  ( NASDAQ:ACRS ) ", "url": "https://www.benzinga.com/news/earnings/24/01/36580279/nasdaq-gains-50-points-us-crude-inventories-rise-last-week", "time_published": "20240110T170400", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 50 points on Wednesday. The Dow traded up 0.17% to 37,588.15 while the NASDAQ rose 0.34% to 14,908.42. The S&P 500 also rose, gaining, 0.21% to 4,766.64. Communication services shares rose by 0.8% on ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/10/crude_oil_6-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.024303, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AEHR", "relevance_score": "0.162802", "ticker_sentiment_score": "-0.087733", "ticker_sentiment_label": "Neutral"}, {"ticker": "DCGO", "relevance_score": "0.162802", "ticker_sentiment_score": "0.012671", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACRS", "relevance_score": "0.162802", "ticker_sentiment_score": "-0.02929", "ticker_sentiment_label": "Neutral"}, {"ticker": "KITT", "relevance_score": "0.242084", "ticker_sentiment_score": "0.477185", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMRN", "relevance_score": "0.162802", "ticker_sentiment_score": "0.248556", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.162802", "ticker_sentiment_score": "0.112122", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Surges 100 Points; PriceSmart Earnings Top Views - Aclaris Therapeutics  ( NASDAQ:ACRS ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/earnings/24/01/36577360/dow-surges-100-points-pricesmart-earnings-top-views", "time_published": "20240110T145056", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher this morning, with the Dow Jones index gaining over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.27% to 37,627.83 while the NASDAQ rose 0.24% to 14,893.51. The S&P 500 also rose, gaining, 0.23% to 4,767.44.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/10/image34.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.038898, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DCGO", "relevance_score": "0.164468", "ticker_sentiment_score": "0.012759", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACRS", "relevance_score": "0.164468", "ticker_sentiment_score": "-0.029493", "ticker_sentiment_label": "Neutral"}, {"ticker": "KITT", "relevance_score": "0.244518", "ticker_sentiment_score": "0.480365", "ticker_sentiment_label": "Bullish"}, {"ticker": "CMND", "relevance_score": "0.322023", "ticker_sentiment_score": "-0.156705", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVNI", "relevance_score": "0.164468", "ticker_sentiment_score": "0.276489", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PSMT", "relevance_score": "0.244518", "ticker_sentiment_score": "0.253699", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Completed Type A Meeting with the FDA", "url": "https://www.globenewswire.com/news-release/2024/01/10/2806995/0/en/Clearmind-Medicine-Completed-Type-A-Meeting-with-the-FDA.html", "time_published": "20240110T121800", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2024 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.116908, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NHPEF", "relevance_score": "0.100308", "ticker_sentiment_score": "0.030541", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.38588", "ticker_sentiment_score": "0.126014", "ticker_sentiment_label": "Neutral"}]}, {"title": "Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More - ATAI Life Sciences  ( NASDAQ:ATAI ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/general/biotech/24/01/36518391/psyched-ibogaine-for-tbi-kentucky-initiative-stalled-dea-quotas-insurance-codes-atais-50m-and-mor", "time_published": "20240107T173634", "authors": ["Lara Goldstein"], "summary": "Results of a first-in-class clinical trial on ibogaine-magnesium therapy for Special Operations Veterans ( SOV ) with repeated blast exposure have been published in the journal Nature. Although preliminary, outcomes have long been awaited as they provide evidence of ibogaine's neuro-restorative ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/05/psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.16017, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DRUG", "relevance_score": "0.104683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IXHL", "relevance_score": "0.104683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPS", "relevance_score": "0.104683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVB", "relevance_score": "0.104683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNMD", "relevance_score": "0.104683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.118564", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.110976", "ticker_sentiment_label": "Neutral"}, {"ticker": "SILO", "relevance_score": "0.104683", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments", "url": "https://www.globenewswire.com/news-release/2024/01/04/2803859/0/en/SciSparc-and-Clearmind-Medicine-Reflect-on-Successful-Collaboration-in-2023-Aiming-to-Upgrade-Wide-Range-of-Psychedelic-Based-Treatments.html", "time_published": "20240104T121800", "authors": ["SciSparc Ltd"], "summary": "The collaboration included six different provisional patent applications filed by Clearmind with the United States Patent and Trademark Office in February 2023 to protect the novel combinations of psychedelics with SciSparc's PEA ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.225199, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.669433", "ticker_sentiment_score": "0.33728", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.192183", "ticker_sentiment_score": "0.15009", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments", "url": "https://www.globenewswire.com/news-release/2024/01/04/2803860/0/en/Clearmind-Medicine-and-SciSparc-Reflect-on-Successful-Collaboration-in-2023-Aiming-to-Upgrade-Wide-Range-of-Psychedelic-Based-Treatments.html", "time_published": "20240104T121800", "authors": ["Clearmind Medicine Inc."], "summary": "The collaboration included filing six different US patent applications with the United States Patent and Trademark Office to protect novel combinations of psychedelics with SciSparc's PEA ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.156893, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.274981", "ticker_sentiment_score": "0.144818", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.159305", "ticker_sentiment_score": "0.140202", "ticker_sentiment_label": "Neutral"}]}, {"title": "Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More - Awakn Life Sciences  ( OTC:AWKNF ) , ATAI Life Sciences  ( NASDAQ:ATAI ) ", "url": "https://www.benzinga.com/markets/cannabis/23/12/36390332/psyched-biden-approves-psychedelics-trials-rfk-australias-first-legal-dedicated-clinic-more", "time_published": "20231227T150926", "authors": ["Lara Goldstein"], "summary": "President Biden signed into law the 2024 National Defense Authorization Act ( NDAA ) , large-scale legislation that also contains a mandate to fund clinical trials with psychedelics for active service members.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/26/psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.129429, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRUG", "relevance_score": "0.059194", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IXHL", "relevance_score": "0.118064", "ticker_sentiment_score": "0.070537", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPS", "relevance_score": "0.118064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVB", "relevance_score": "0.059194", "ticker_sentiment_score": "-0.102998", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUGE", "relevance_score": "0.059194", "ticker_sentiment_score": "0.462851", "ticker_sentiment_label": "Bullish"}, {"ticker": "JAQC", "relevance_score": "0.029618", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNMD", "relevance_score": "0.059194", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.059194", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.059194", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SILO", "relevance_score": "0.059194", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More - Bright Minds Biosciences  ( NASDAQ:DRUG ) , Incannex Healthcare  ( NASDAQ:IXHL ) , Compass Pathways  ( NASDAQ:CMPS ) , GH Research  ( NASDAQ:GHRS ) ", "url": "https://www.benzinga.com/markets/cannabis/23/12/36284691/psyched-bidens-big-decision-on-psychedelics-therapy-lsd-anxiety-results-matthew-perry-autopsy-an", "time_published": "20231218T172139", "authors": ["Lara Goldstein"], "summary": "President Joe Biden received the final version of a large-scale defense bill providing funding for psychedelics clinical trials for military service members.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/18/psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.057439, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRUG", "relevance_score": "0.079", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IXHL", "relevance_score": "0.079", "ticker_sentiment_score": "0.053417", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPS", "relevance_score": "0.079", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVB", "relevance_score": "0.079", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNMD", "relevance_score": "0.157227", "ticker_sentiment_score": "-0.020643", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.079", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.079", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SILO", "relevance_score": "0.079", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards", "url": "https://www.globenewswire.com/news-release/2023/12/14/2796248/0/en/Clearmind-Medicine-Announces-It-Is-In-Compliance-with-All-Applicable-Nasdaq-Listing-Standards.html", "time_published": "20231214T132600", "authors": ["Clearmind Medicine Inc."], "summary": "Nasdaq Has Informed the Company That a Bid Price Deficiency of its Common Shares Has Been CuredTel Aviv, Israel / Vancouver, Canada, Dec. 14, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.928769"}], "overall_sentiment_score": 0.116463, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AWON", "relevance_score": "0.058615", "ticker_sentiment_score": "0.131191", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.174587", "ticker_sentiment_score": "0.13796", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - African Agriculture Hldgs  ( NASDAQ:AAGR ) , Achieve Life Sciences  ( NASDAQ:ACHV ) ", "url": "https://www.benzinga.com/news/23/12/36203637/why-johnson-controls-international-shares-are-trading-lower-by-over-6-here-are-other-stocks-moving-i", "time_published": "20231212T182222", "authors": ["Avi Kapoor"], "summary": "Shares of Johnson Controls International plc JCI moved lower during Tuesday's session following weak quarterly results. Johnson Controls reported fourth-quarter FY23 sales growth of 2.7% year-on-year to $6.91 billion ( +2% organically ) , missing the consensus of $7.09 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/12/johnson_controls_-_logo_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.004915, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GPRO", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.23201", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HRYU", "relevance_score": "0.098862", "ticker_sentiment_score": "0.177522", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IONM", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.05508", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOTU", "relevance_score": "0.098862", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BQ", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.527993", "ticker_sentiment_label": "Bearish"}, {"ticker": "ODC", "relevance_score": "0.098862", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IXHL", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.355698", "ticker_sentiment_label": "Bearish"}, {"ticker": "SBOW", "relevance_score": "0.147818", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLBD", "relevance_score": "0.098862", "ticker_sentiment_score": "0.302021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAGR", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.400682", "ticker_sentiment_label": "Bearish"}, {"ticker": "HPCO", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.091847", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAVA", "relevance_score": "0.098862", "ticker_sentiment_score": "0.365348", "ticker_sentiment_label": "Bullish"}, {"ticker": "CLINR", "relevance_score": "0.049526", "ticker_sentiment_score": "0.26031", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPEC", "relevance_score": "0.147818", "ticker_sentiment_score": "0.38753", "ticker_sentiment_label": "Bullish"}, {"ticker": "CCCC", "relevance_score": "0.098862", "ticker_sentiment_score": "0.112349", "ticker_sentiment_label": "Neutral"}, {"ticker": "BON", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.527993", "ticker_sentiment_label": "Bearish"}, {"ticker": "HCDI", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.293471", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GGE", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.200022", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "INAB", "relevance_score": "0.049526", "ticker_sentiment_score": "0.101192", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.049526", "ticker_sentiment_score": "-0.183132", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VPGLF", "relevance_score": "0.049526", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.130193", "ticker_sentiment_label": "Neutral"}, {"ticker": "APPS", "relevance_score": "0.098862", "ticker_sentiment_score": "0.365348", "ticker_sentiment_label": "Bullish"}, {"ticker": "ICG", "relevance_score": "0.098862", "ticker_sentiment_score": "0.08632", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACHV", "relevance_score": "0.196212", "ticker_sentiment_score": "-0.042783", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLX", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.189072", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JCI", "relevance_score": "0.196212", "ticker_sentiment_score": "-0.029817", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.005696", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.049526", "ticker_sentiment_score": "-0.001993", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALTNF", "relevance_score": "0.049526", "ticker_sentiment_score": "0.26031", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADTX", "relevance_score": "0.098862", "ticker_sentiment_score": "0.268718", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CADL", "relevance_score": "0.098862", "ticker_sentiment_score": "-0.00791", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNTK", "relevance_score": "0.147818", "ticker_sentiment_score": "0.111895", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRSH", "relevance_score": "0.098862", "ticker_sentiment_score": "0.333164", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EGLE", "relevance_score": "0.147818", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.196212", "ticker_sentiment_score": "-0.00313", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNE", "relevance_score": "0.098862", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.210557", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:ADX", "relevance_score": "0.049526", "ticker_sentiment_score": "-0.272347", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Assembly Biosciences  ( NASDAQ:ASMB ) , Achieve Life Sciences  ( NASDAQ:ACHV ) ", "url": "https://www.benzinga.com/news/23/12/36194643/why-icosavax-shares-are-trading-higher-by-around-45-here-are-20-stocks-moving-premarket", "time_published": "20231212T130008", "authors": ["Avi Kapoor"], "summary": "Shares of Icosavax, Inc. ICVX rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. Icosavax also reported topline interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/12/image34.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.865346"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.085257, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HCDI", "relevance_score": "0.232069", "ticker_sentiment_score": "-0.174061", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "XCUR", "relevance_score": "0.155954", "ticker_sentiment_score": "-0.057391", "ticker_sentiment_label": "Neutral"}, {"ticker": "INAB", "relevance_score": "0.078354", "ticker_sentiment_score": "0.092273", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNTB", "relevance_score": "0.232069", "ticker_sentiment_score": "0.043077", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTX", "relevance_score": "0.155954", "ticker_sentiment_score": "0.143868", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRYU", "relevance_score": "0.155954", "ticker_sentiment_score": "0.176959", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IONM", "relevance_score": "0.155954", "ticker_sentiment_score": "-0.057391", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.232069", "ticker_sentiment_score": "-0.155597", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ACHV", "relevance_score": "0.232069", "ticker_sentiment_score": "-0.158367", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KAVL", "relevance_score": "0.155954", "ticker_sentiment_score": "0.135185", "ticker_sentiment_label": "Neutral"}, {"ticker": "WULF", "relevance_score": "0.155954", "ticker_sentiment_score": "0.239698", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLBD", "relevance_score": "0.155954", "ticker_sentiment_score": "0.333386", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.078354", "ticker_sentiment_score": "0.109398", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPCO", "relevance_score": "0.155954", "ticker_sentiment_score": "-0.087203", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASMB", "relevance_score": "0.155954", "ticker_sentiment_score": "-0.387681", "ticker_sentiment_label": "Bearish"}, {"ticker": "ATXI", "relevance_score": "0.155954", "ticker_sentiment_score": "0.084576", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRSH", "relevance_score": "0.155954", "ticker_sentiment_score": "0.341018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TENX", "relevance_score": "0.155954", "ticker_sentiment_score": "0.255", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICVX", "relevance_score": "0.377142", "ticker_sentiment_score": "0.3247", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.232069", "ticker_sentiment_score": "-0.247013", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:PAY", "relevance_score": "0.078354", "ticker_sentiment_score": "0.199374", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More - ATAI Life Sciences  ( NASDAQ:ATAI ) , Braxia Scientific  ( OTC:BRAXF ) ", "url": "https://www.benzinga.com/markets/cannabis/23/12/36167186/psyched-john-lennon-remembered-clinical-trials-for-service-members-chrissy-teigen-jon-feliciano-", "time_published": "20231211T154327", "authors": ["Lara Goldstein"], "summary": "The world seemed to come to a momentary halt on December 8, 1980, when news that John Lennon was shot and killed as he approached his apartment building in New York City came out. Lennon's untimely death sent shockwaves around the world. His contributions to music, activism and peace continue to ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/09/psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.090539, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRUG", "relevance_score": "0.087824", "ticker_sentiment_score": "0.142596", "ticker_sentiment_label": "Neutral"}, {"ticker": "IXHL", "relevance_score": "0.087824", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPS", "relevance_score": "0.174587", "ticker_sentiment_score": "0.004381", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVB", "relevance_score": "0.087824", "ticker_sentiment_score": "-0.061793", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNMD", "relevance_score": "0.087824", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.087824", "ticker_sentiment_score": "-0.070057", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.087824", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SILO", "relevance_score": "0.087824", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crude Oil Moves Lower; AutoZone Profit Tops Views - AutoZone  ( NYSE:AZO ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36099575/crude-oil-moves-lower-autozone-profit-tops-views", "time_published": "20231205T192749", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500 also fell, dropping, 0.07% to 4,566.73. Information technology shares rose by 0.4% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/05/image44.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.023877, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TVTX", "relevance_score": "0.119235", "ticker_sentiment_score": "0.22121", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZO", "relevance_score": "0.119235", "ticker_sentiment_score": "0.324864", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.119235", "ticker_sentiment_score": "0.01853", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.235823", "ticker_sentiment_score": "-0.059756", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBI", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.054212", "ticker_sentiment_label": "Neutral"}, {"ticker": "MFH", "relevance_score": "0.119235", "ticker_sentiment_score": "0.25772", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.119235", "ticker_sentiment_score": "0.129998", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Falls 100 Points; ISM Services PMI Increases In November - Allarity Therapeutics  ( NASDAQ:ALLR ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36097189/dow-falls-100-points-ism-services-pmi-increases-in-november", "time_published": "20231205T171148", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&P 500 also fell, dropping, 0.03% to 4,568.46. Consumer discretionary shares rose by 0.7% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/05/image47.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.021511, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.126784", "ticker_sentiment_score": "0.019075", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.250386", "ticker_sentiment_score": "-0.062748", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBI", "relevance_score": "0.126784", "ticker_sentiment_score": "-0.055857", "ticker_sentiment_label": "Neutral"}, {"ticker": "MFH", "relevance_score": "0.126784", "ticker_sentiment_score": "0.264621", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALLR", "relevance_score": "0.126784", "ticker_sentiment_score": "0.072664", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.126784", "ticker_sentiment_score": "0.133564", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Clearmind Stock Is Climbing Higher Tuesday - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/23/12/36093387/why-clearmind-stock-is-climbing-higher-tuesday", "time_published": "20231205T152121", "authors": ["Adam Eckert"], "summary": "Clearmind Medicine Inc CMND shares are trading higher Tuesday after the company announced results in its cocaine addiction treatment. What Happened: Clearmind said it achieved positive results in addiction treatment testing of the company's innovative psychedelic molecule MEAI.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/05/blur-1853262_1920-12.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.256596, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.720339", "ticker_sentiment_score": "0.541852", "ticker_sentiment_label": "Bullish"}]}, {"title": "Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More - ATAI Life Sciences  ( NASDAQ:ATAI ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/12/36066535/psyched-defense-dept-s-ketamine-trial-cybins-psilocybin-metabolic-disorders-reform-update-and-mo", "time_published": "20231205T151201", "authors": ["Lara Goldstein"], "summary": "A DOD Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos Therapeutics SEEL.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/04/psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.188456, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DRUG", "relevance_score": "0.087503", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IXHL", "relevance_score": "0.087503", "ticker_sentiment_score": "0.229956", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMPS", "relevance_score": "0.087503", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVB", "relevance_score": "0.087503", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRC", "relevance_score": "0.087503", "ticker_sentiment_score": "-0.088848", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNMD", "relevance_score": "0.087503", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.173958", "ticker_sentiment_score": "-0.094361", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.258351", "ticker_sentiment_score": "0.111744", "ticker_sentiment_label": "Neutral"}, {"ticker": "SILO", "relevance_score": "0.087503", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment", "url": "https://www.globenewswire.com/news-release/2023/12/05/2790952/0/en/Clearmind-Medicine-Achieved-Positive-Results-in-Cocaine-Addiction-Treatment.html", "time_published": "20231205T134700", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.150348, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.131164", "ticker_sentiment_score": "0.107984", "ticker_sentiment_label": "Neutral"}, {"ticker": "NHPEF", "relevance_score": "0.087663", "ticker_sentiment_score": "0.023248", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.21686", "ticker_sentiment_score": "0.233006", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Aditxt  ( NASDAQ:ADTX ) , Ampio Pharmaceuticals  ( AMEX:AMPE ) ", "url": "https://www.benzinga.com/news/23/11/36020980/why-salesforce-shares-are-trading-higher-by-over-9-here-are-20-stocks-moving-premarket", "time_published": "20231130T130137", "authors": ["Lisa Levin"], "summary": "Shares of Salesforce, Inc. CRM shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates. Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/30/salesforce_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.187474, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VFS", "relevance_score": "0.132368", "ticker_sentiment_score": "0.348153", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "YOSH", "relevance_score": "0.197413", "ticker_sentiment_score": "-0.133514", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVNI", "relevance_score": "0.132368", "ticker_sentiment_score": "0.005398", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYCC", "relevance_score": "0.132368", "ticker_sentiment_score": "0.085165", "ticker_sentiment_label": "Neutral"}, {"ticker": "NMRA", "relevance_score": "0.261117", "ticker_sentiment_score": "0.26139", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CNXA", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.039806", "ticker_sentiment_label": "Neutral"}, {"ticker": "VVOS", "relevance_score": "0.197413", "ticker_sentiment_score": "0.115914", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLM", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.356381", "ticker_sentiment_label": "Bearish"}, {"ticker": "RDHL", "relevance_score": "0.197413", "ticker_sentiment_score": "0.318302", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGD", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.223539", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PSTG", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.045663", "ticker_sentiment_label": "Neutral"}, {"ticker": "KTTA", "relevance_score": "0.132368", "ticker_sentiment_score": "0.123087", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADTX", "relevance_score": "0.132368", "ticker_sentiment_score": "0.233085", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CISS", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.223539", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ATXI", "relevance_score": "0.197413", "ticker_sentiment_score": "0.120461", "ticker_sentiment_label": "Neutral"}, {"ticker": "OSA", "relevance_score": "0.132368", "ticker_sentiment_score": "0.130204", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.197413", "ticker_sentiment_score": "-0.262297", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MINM", "relevance_score": "0.132368", "ticker_sentiment_score": "0.348153", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Clearmind Medicine Stock Is Moving Today - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/23/11/35988773/why-clearmind-medicine-stock-is-moving-today", "time_published": "20231128T205518", "authors": ["Ryan Gustafson"], "summary": "Clearmind Medicine Inc. CMND shares are trading higher on Tuesday after the company announced results from its weight loss and metabolic disorder program. What To Know: The company announced positive results from its pre-clinical trial, which utilized a treatment which combined Clearmind's MEAI ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/28/medicine-8287535_12804.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.301386, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.514619", "ticker_sentiment_score": "0.099324", "ticker_sentiment_label": "Neutral"}]}, {"title": "SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment", "url": "https://www.globenewswire.com/news-release/2023/11/28/2786939/0/en/SciSparc-Announces-Positive-Results-from-its-Weight-Loss-and-Metabolic-Disorder-Program-with-its-Proprietary-Psychedelic-Based-Treatment.html", "time_published": "20231128T132500", "authors": ["SciSparc Ltd"], "summary": "The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide\u2122 and Clearmind Medicine's MEAI molecule ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.170223, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.402761", "ticker_sentiment_score": "0.18432", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.09347", "ticker_sentiment_score": "0.014233", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment", "url": "https://www.globenewswire.com/news-release/2023/11/28/2786940/0/en/Clearmind-Medicine-Announces-Positive-Results-from-its-Weight-Loss-and-Metabolic-Disorder-Program-with-its-Proprietary-Psychedelic-Based-Treatment.html", "time_published": "20231128T132500", "authors": ["Clearmind Medicine Inc."], "summary": "Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.18736, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.10863", "ticker_sentiment_score": "0.159727", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "EXCLUSIVE: Clearmind Medicine's Psychedelic-Based Treatment Shows Encouraging Preclinical Activity In Obesity, Metabolic Disorders - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35973403/exclusive-clearmind-medicines-psychedelic-based-treatment-shows-encouraging-preclinical-activity-", "time_published": "20231128T130021", "authors": ["Vandana Singh"], "summary": "Clearmind Medicine Inc CMND has released results from its pre-clinical trial of the combination therapy.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/28/cmnd.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.124622, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.297661", "ticker_sentiment_score": "-0.244799", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CMND", "relevance_score": "0.433523", "ticker_sentiment_score": "0.343661", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures", "url": "https://www.globenewswire.com/news-release/2023/11/27/2786196/0/en/Clearmind-Medicine-to-Participate-in-Traditional-vs-Novel-Psychedelics-Virtual-Event-with-Leading-Industry-Figures.html", "time_published": "20231127T135500", "authors": ["Clearmind Medicine Inc."], "summary": "Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and changing international psychedelic space ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.230073, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.439026", "ticker_sentiment_score": "0.41805", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why UP Fintech Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - AgriFORCE Growing Systems  ( NASDAQ:AGRI ) , Apollomics  ( NASDAQ:APLM ) ", "url": "https://www.benzinga.com/news/23/11/35956771/why-up-fintech-shares-are-trading-higher-by-around-7-here-are-20-stocks-moving-premarket", "time_published": "20231127T131025", "authors": ["Lisa Levin"], "summary": "Shares of UP Fintech Holding Limited TIGR surged in pre-market trading after the company results for the third quarter. UP Fintech Holding posted adjusted EPADS of 10 cents up from 4 cents in the year-ago period. The company's quarterly sales came in at $70.10 million versus, $55.41 million a ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/27/image_5.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.865346"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.12545, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CNEY", "relevance_score": "0.145145", "ticker_sentiment_score": "0.311641", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IMPL", "relevance_score": "0.216215", "ticker_sentiment_score": "0.321438", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BGLC", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.234624", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PGY", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.005138", "ticker_sentiment_label": "Neutral"}, {"ticker": "CUEN", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.238661", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FLJ", "relevance_score": "0.216215", "ticker_sentiment_score": "0.34477", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TIGR", "relevance_score": "0.285526", "ticker_sentiment_score": "0.088074", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRKN", "relevance_score": "0.145145", "ticker_sentiment_score": "0.220884", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APLM", "relevance_score": "0.145145", "ticker_sentiment_score": "0.069925", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKIT", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.219635", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TRVN", "relevance_score": "0.216215", "ticker_sentiment_score": "-0.062431", "ticker_sentiment_label": "Neutral"}, {"ticker": "INBS", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.053273", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOBQ", "relevance_score": "0.145145", "ticker_sentiment_score": "0.327663", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MIND", "relevance_score": "0.072876", "ticker_sentiment_score": "0.215095", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CYN", "relevance_score": "0.145145", "ticker_sentiment_score": "0.385071", "ticker_sentiment_label": "Bullish"}, {"ticker": "ATXI", "relevance_score": "0.145145", "ticker_sentiment_score": "0.33381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MVLA", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.372932", "ticker_sentiment_label": "Bearish"}, {"ticker": "BPTH", "relevance_score": "0.216215", "ticker_sentiment_score": "-0.008842", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAPT", "relevance_score": "0.145145", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.216215", "ticker_sentiment_score": "-0.048479", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine's Reverse Stock Split And Nasdaq Delisting Notice - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/11/35903164/clearmind-medicines-reverse-stock-split-and-nasdaq-delisting-notice", "time_published": "20231121T192542", "authors": ["Lara Goldstein"], "summary": "Clearmind Medicine Inc. CMND is set to conduct a 1-for-30 reverse share split of its issued and outstanding ordinary shares, no par value, effective starting Nov. 28, 2023. Common shares will be adjusted from 18,221,419 to 607,381.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/21/lawyer_psychedelic_cannabis_flametric_aiyoshi597_gisele_yashar_bacsica_and_freedomz_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.28913, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.102888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.204072", "ticker_sentiment_score": "0.250848", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Announces 1-for-30 Reverse Share Split", "url": "https://www.globenewswire.com/news-release/2023/11/21/2784036/0/en/Clearmind-Medicine-Announces-1-for-30-Reverse-Share-Split.html", "time_published": "20231121T131500", "authors": ["Clearmind Medicine Inc."], "summary": "Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.176803, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.151539", "ticker_sentiment_score": "0.111764", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35857161/clearmind-medicine-announces-receipt-of-nasdaq-delisting-notice-and-plan-for-immediate-recomplianc", "time_published": "20231117T211500", "authors": ["Globe Newswire"], "summary": "As part of the Company's plan for recompliance, the Company's shareholders approved a reverse stock split on November 14, 2023.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.999921"}], "overall_sentiment_score": 0.100143, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.09402", "ticker_sentiment_score": "0.106071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance", "url": "https://www.globenewswire.com/news-release/2023/11/17/2782735/0/en/Clearmind-Medicine-Announces-Receipt-of-Nasdaq-Delisting-Notice-and-Plan-for-Immediate-Recompliance.html", "time_published": "20231117T211500", "authors": ["Clearmind Medicine Inc."], "summary": "As part of the Company's plan for recompliance, the Company's shareholders approved a reverse stock split on November 14, 2023.", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.999767"}], "overall_sentiment_score": 0.105089, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.143415", "ticker_sentiment_score": "0.143531", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces Shareholders Meeting Results", "url": "https://www.globenewswire.com/news-release/2023/11/15/2780945/0/en/Clearmind-Medicine-Announces-Shareholders-Meeting-Results.html", "time_published": "20231115T123700", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, Nov. 15, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"Company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.270164, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.362505", "ticker_sentiment_score": "0.340263", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities", "url": "https://www.globenewswire.com/news-release/2023/11/09/2777480/0/en/Clearmind-Medicine-to-Pioneer-Psychedelic-Clinical-Trials-for-Alcohol-Use-Disorder-with-Ivy-League-Universities.html", "time_published": "20231109T142000", "authors": ["Clearmind Medicine Inc."], "summary": "Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.064744, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.379291", "ticker_sentiment_score": "0.077072", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why BSQUARE Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket - AgileThought  ( NASDAQ:AGIL ) , Agape ATP  ( NASDAQ:ATPC ) ", "url": "https://www.benzinga.com/news/23/10/35217585/why-bsquare-shares-are-trading-higher-by-around-44-here-are-20-stocks-moving-premarket", "time_published": "20231012T132934", "authors": ["Lisa Levin"], "summary": "OpGen, Inc. OPGN shares rose 432% to $1.79 in pre-market trading. Opgen said on Oct. 6, unit Curetis GMBH received payment of 750,000 euros related to the sale of certain Unyvero A50 Systems by Curetis to a strategic partner.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/12/image40.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.865346"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.029564, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AATP", "relevance_score": "0.083541", "ticker_sentiment_score": "-0.0467", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOC", "relevance_score": "0.166169", "ticker_sentiment_score": "0.08355", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTEK", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.273419", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TAOP", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.196065", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JAGX", "relevance_score": "0.166169", "ticker_sentiment_score": "0.354086", "ticker_sentiment_label": "Bullish"}, {"ticker": "LXEH", "relevance_score": "0.166169", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSQR", "relevance_score": "0.246999", "ticker_sentiment_score": "0.345957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OPGN", "relevance_score": "0.246999", "ticker_sentiment_score": "0.194908", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RSLS", "relevance_score": "0.246999", "ticker_sentiment_score": "0.313407", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SGD", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.259634", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JYD", "relevance_score": "0.166169", "ticker_sentiment_score": "0.034272", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGIL", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.018016", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRGT", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.273419", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SECO", "relevance_score": "0.166169", "ticker_sentiment_score": "0.360835", "ticker_sentiment_label": "Bullish"}, {"ticker": "TPST", "relevance_score": "0.325208", "ticker_sentiment_score": "0.09788", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHIO", "relevance_score": "0.246999", "ticker_sentiment_score": "-0.196948", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VINO", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.270602", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VS", "relevance_score": "0.166169", "ticker_sentiment_score": "0.354086", "ticker_sentiment_label": "Bullish"}, {"ticker": "CMND", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.254502", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WHLR", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.059896", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th", "url": "https://www.globenewswire.com/news-release/2023/10/05/2755423/0/en/Clearmind-Medicine-to-Present-at-the-8th-Annual-Dawson-James-Conference-on-October-12th.html", "time_published": "20231005T130000", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, Oct. 05, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0777b20d-1f01-4def-a3c1-977bf158492c", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.988915"}], "overall_sentiment_score": 0.139404, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.221819", "ticker_sentiment_score": "0.172198", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Closes US$2.25 Million Public Offering", "url": "https://www.globenewswire.com/news-release/2023/09/18/2745083/0/en/Clearmind-Medicine-Closes-US-2-25-Million-Public-Offering.html", "time_published": "20230918T161600", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( NASDAQ: CMND ) ( CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" ) , a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.875462"}], "overall_sentiment_score": 0.094948, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.174272", "ticker_sentiment_score": "0.124636", "ticker_sentiment_label": "Neutral"}]}, {"title": "Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind's $2.25M Public Offering - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/09/34595165/psychedelics-capital-moves-beckley-waves-raises-3-3m-clearminds-2-25m-public-offering", "time_published": "20230915T160918", "authors": ["Lara Goldstein"], "summary": "Beckley Waves, a U.K.-based venture studio co-founded by \"Queen of Psychedelics\" Amanda Feilding with angel investors like FJ Labs, Courtney & Carter Reum, Joanne Wilson and actress Rosamund Pike, recently closed a $3.3 million ( +10% than original target ) funding round, saying that investors' ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/14/finance_and_psychedelics_publicdomainpictures_janjf93_by_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.409861, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.146025", "ticker_sentiment_score": "-0.093908", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Surges 100 Points; First Wave BioPharma Shares Spike Higher - Biolase  ( NASDAQ:BIOL ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/earnings/23/09/34591297/nasdaq-surges-100-points-first-wave-biopharma-shares-spike-higher", "time_published": "20230914T183007", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.93% to 34,898.47 while the NASDAQ rose 0.75% to 13,917.44. The S&P 500, also rose, gaining, 0.77% to 4,501.69. Real estate shares jumped by 1.6% on Thursday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/14/image11.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.187681, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FWBI", "relevance_score": "0.137278", "ticker_sentiment_score": "0.305121", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIOL", "relevance_score": "0.137278", "ticker_sentiment_score": "0.016106", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.204647", "ticker_sentiment_score": "0.270794", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GXO", "relevance_score": "0.068896", "ticker_sentiment_score": "0.225279", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFSW", "relevance_score": "0.137278", "ticker_sentiment_score": "0.271326", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.068896", "ticker_sentiment_score": "0.25357", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Crude Oil Rises Sharply; BIOLASE Shares Plunge - Biolase  ( NASDAQ:BIOL ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/earnings/23/09/34587190/crude-oil-rises-sharply-biolase-shares-plunge", "time_published": "20230914T161953", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.61% to 34,784.94 while the NASDAQ rose 0.71% to 13,911.78. The S&P 500, also rose, gaining, 0.64% to 4,495.82. Energy shares jumped by 1.2% on Thursday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/14/crude_oil_6-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.196925, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FWBI", "relevance_score": "0.138464", "ticker_sentiment_score": "0.30645", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIOL", "relevance_score": "0.138464", "ticker_sentiment_score": "0.016183", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.206392", "ticker_sentiment_score": "0.272485", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GXO", "relevance_score": "0.069495", "ticker_sentiment_score": "0.22541", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFSW", "relevance_score": "0.138464", "ticker_sentiment_score": "0.272526", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.069495", "ticker_sentiment_score": "0.253722", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dow Jumps Over 200 Points; US Producer Prices Rise In August - Biolase  ( NASDAQ:BIOL ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/earnings/23/09/34582871/dow-jumps-over-200-points-us-producer-prices-rise-in-august", "time_published": "20230914T140356", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.71% to 34,820.58 while the NASDAQ rose 0.27% to 13,849.49. The S&P 500, also rose, gaining, 0.53% to 4,491.20. Energy shares jumped by 1.4% on Thursday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/14/image33.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.185545, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SEZNL", "relevance_score": "0.079392", "ticker_sentiment_score": "0.273638", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FWBI", "relevance_score": "0.158", "ticker_sentiment_score": "0.329516", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIOL", "relevance_score": "0.158", "ticker_sentiment_score": "0.017535", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPTD", "relevance_score": "0.158", "ticker_sentiment_score": "0.494892", "ticker_sentiment_label": "Bullish"}, {"ticker": "CMND", "relevance_score": "0.235062", "ticker_sentiment_score": "0.300254", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GXO", "relevance_score": "0.079392", "ticker_sentiment_score": "0.22843", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFSW", "relevance_score": "0.158", "ticker_sentiment_score": "0.293413", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.079392", "ticker_sentiment_score": "0.257189", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Novo Integrated Sciences Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket - Avalo Therapeutics  ( NASDAQ:AVTX ) , Biolase  ( NASDAQ:BIOL ) ", "url": "https://www.benzinga.com/news/23/09/34577092/why-novo-integrated-sciences-shares-are-trading-higher-by-9-here-are-20-stocks-moving-premarket", "time_published": "20230914T120504", "authors": ["Lisa Levin"], "summary": "TransCode Therapeutics, Inc. RNAZ shares rose 43.3% to $1.29 in pre-market trading. Avalo Therapeutics, Inc. AVTX shares rose 39.5% to $0.3122 in pre-market trading after jumping 81% on Wednesday. Avalo Therapeutics recently agreed to divest AVTX-800 series. Esports Entertainment Group, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/14/image34.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.041658, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.084722", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCT", "relevance_score": "0.16849", "ticker_sentiment_score": "-0.0919", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMPL", "relevance_score": "0.16849", "ticker_sentiment_score": "-0.256791", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LYT", "relevance_score": "0.16849", "ticker_sentiment_score": "0.185967", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVTX", "relevance_score": "0.329551", "ticker_sentiment_score": "0.393178", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVOS", "relevance_score": "0.250386", "ticker_sentiment_score": "0.472467", "ticker_sentiment_label": "Bullish"}, {"ticker": "SALM", "relevance_score": "0.16849", "ticker_sentiment_score": "0.376784", "ticker_sentiment_label": "Bullish"}, {"ticker": "BNOX", "relevance_score": "0.16849", "ticker_sentiment_score": "-0.269393", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LXEH", "relevance_score": "0.16849", "ticker_sentiment_score": "0.267615", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EMMLD", "relevance_score": "0.084722", "ticker_sentiment_score": "-0.109555", "ticker_sentiment_label": "Neutral"}, {"ticker": "EIGR", "relevance_score": "0.250386", "ticker_sentiment_score": "-0.12615", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMBL", "relevance_score": "0.16849", "ticker_sentiment_score": "0.515529", "ticker_sentiment_label": "Bullish"}, {"ticker": "RNAZ", "relevance_score": "0.16849", "ticker_sentiment_score": "0.267615", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NIR", "relevance_score": "0.16849", "ticker_sentiment_score": "0.089094", "ticker_sentiment_label": "Neutral"}, {"ticker": "FAMI", "relevance_score": "0.16849", "ticker_sentiment_score": "-0.40536", "ticker_sentiment_label": "Bearish"}, {"ticker": "BIOL", "relevance_score": "0.16849", "ticker_sentiment_score": "-0.045466", "ticker_sentiment_label": "Neutral"}, {"ticker": "FFIE", "relevance_score": "0.16849", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.16849", "ticker_sentiment_score": "-0.0919", "ticker_sentiment_label": "Neutral"}]}, {"title": "Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More - Awakn Life Sciences  ( OTC:AWKNF ) , ATAI Life Sciences  ( NASDAQ:ATAI ) ", "url": "https://www.benzinga.com/markets/cannabis/23/09/34371541/psyched-psilocybin-therapy-for-depression-uk-rescheduling-us-policy-reform-and-more", "time_published": "20230911T133416", "authors": ["Lara Goldstein"], "summary": "Nonprofit medical research organization the Usona Institute shared the results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for 104 adults with Major Depressive Disorder ( MDD, ) providing further evidence of the psychedelic's antidepressant capabilities.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/08/psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.140304, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRUG", "relevance_score": "0.088635", "ticker_sentiment_score": "-0.114768", "ticker_sentiment_label": "Neutral"}, {"ticker": "IXHL", "relevance_score": "0.088635", "ticker_sentiment_score": "0.086749", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPS", "relevance_score": "0.17618", "ticker_sentiment_score": "0.038744", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVB", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUGE", "relevance_score": "0.088635", "ticker_sentiment_score": "-0.07846", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNMD", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.088635", "ticker_sentiment_score": "0.122042", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SILO", "relevance_score": "0.088635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Grants SpiSparc, Ltd. Extension To Maintain Listing: +600% Bid Price Surge Needed - SciSparc  ( NASDAQ:SPRC ) ", "url": "https://www.benzinga.com/markets/cannabis/23/09/34332412/nasdaq-grants-spisparc-ltd-extension-to-maintain-listing-600-bid-price-surge-needed", "time_published": "20230907T194536", "authors": ["Lara Goldstein"], "summary": "Specialty clinical-stage biopharma company SciSparc Ltd. SPRC has received a Nasdaq notice granting the company an additional 180-day compliance period until March 4 to regain compliance with the stock market's minimum bid price rule.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/07/financial_psychedelics_raimundo79_and_blue_planet_studio_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.309554, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.348592", "ticker_sentiment_score": "0.318197", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SSTK", "relevance_score": "0.072", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.143415", "ticker_sentiment_score": "0.271458", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.143415", "ticker_sentiment_score": "-0.071708", "ticker_sentiment_label": "Neutral"}]}, {"title": "Johns Hopkins Will Work With Clearmind On Alcohol Addiction Research Program - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/09/34292211/johns-hopkins-will-work-with-clearmind-on-alcohol-addiction-research-program", "time_published": "20230906T213636", "authors": ["Lara Goldstein"], "summary": "Israeli psychedelics biotech Clearmind Medicine CMND has inked a research agreement with Johns Hopkins University School of Medicine ( JHU ) to conduct the first-in-human Phase I/IIa clinical trial on its proprietary MEAI-based compound CMND-100 for the potential treatment of Alcohol Use ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/06/financial_psychedelics_raimundo79_and_sergey_nivens_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.363429, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.078354", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.444919", "ticker_sentiment_score": "0.270928", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder", "url": "https://www.globenewswire.com/news-release/2023/09/06/2738525/0/en/Clearmind-Medicine-Announces-Clinical-Research-Collaboration-with-Johns-Hopkins-University-to-Evaluate-CMND-100-in-Patients-with-Alcohol-Use-Disorder.html", "time_published": "20230906T132000", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, Sept. 06, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.135001, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.443626", "ticker_sentiment_score": "0.291394", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company", "url": "https://www.globenewswire.com/news-release/2023/08/14/2724388/0/en/Clearmind-Medicine-Announces-Collaboration-with-CTS-Ltd-a-Leading-Pharmaceutical-and-Consumer-Products-Company.html", "time_published": "20230814T122500", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"Company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.257018, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.209365", "ticker_sentiment_score": "0.298865", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33828771/clearmind-medicine-announces-collaboration-with-cts-ltd-a-leading-pharmaceutical-and-consumer-prod", "time_published": "20230814T122500", "authors": ["Globe Newswire"], "summary": "Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( ( Nasdaq, CSE:CMND ) , CWY ( \"Clearmind\" or the \"Company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.245449, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.154125", "ticker_sentiment_score": "0.227216", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Announces Share-Based Payment for the Company's Consultants", "url": "https://www.globenewswire.com/news-release/2023/07/17/2705980/0/en/Clearmind-Medicine-Announces-Share-Based-Payment-for-the-Company-s-Consultants.html", "time_published": "20230717T201500", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.097859, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.202366", "ticker_sentiment_score": "0.187458", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bright Minds Goes For 5:1 Shares Consolidation, Hopes To Regain NASDAQ Compliance - Bright Minds Biosciences  ( NASDAQ:DRUG ) ", "url": "https://www.benzinga.com/markets/cannabis/23/07/33188838/bright-minds-goes-for-5-1-shares-consolidation-hopes-to-regain-nasdaq-compliance", "time_published": "20230711T192546", "authors": ["Lara Goldstein"], "summary": "Bright Minds Biosciences Inc. DRUG is going for a consolidation of its common shares on a five-to-one basis, a plan approved by the company's board of directors in June.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/11/psychedelics_earnings_pexels.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.343132, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DRUG", "relevance_score": "0.279015", "ticker_sentiment_score": "0.33961", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REUN", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.072276", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.072276", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Penny Stocks To Watch Right Now For Under $1", "url": "https://pennystocks.com/featured/2023/06/23/3-penny-stocks-to-watch-right-now-for-under-1/", "time_published": "20230623T175721", "authors": ["J. Samuel"], "summary": "Penny stocks frequently stand out as a remarkable sector teeming with potential. With their generally low price points and volatility, these investment vehicles can present both incredible opportunities and significant risks. Are you interested? So, what exactly are penny stocks? The U.S.", "banner_image": "https://pennystocks.com/wp-content/uploads/2022/11/penny-stocks-to-buy-under-1-right-now-this-week.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.217289, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.032558", "ticker_sentiment_score": "0.050962", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGOPF", "relevance_score": "0.032558", "ticker_sentiment_score": "0.186819", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IRNT", "relevance_score": "0.12969", "ticker_sentiment_score": "0.122025", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.16171", "ticker_sentiment_score": "0.134883", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYZN", "relevance_score": "0.12969", "ticker_sentiment_score": "0.143607", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFGC", "relevance_score": "0.065061", "ticker_sentiment_score": "0.317235", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome", "url": "https://www.globenewswire.com/news-release/2023/06/16/2689752/0/en/SciSparc-and-Clearmind-Medicine-to-Conduct-a-Study-Evaluating-Their-Combination-Treatment-for-Obesity-and-Metabolic-Syndrome.html", "time_published": "20230616T130500", "authors": ["SciSparc Ltd"], "summary": "The treatment combines SciSparc's Palmitoylethanolamide ( PEA ) , the active pharmaceutical ingredient of its proprietary CannAmide\u2122, and Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/bcad2b2c-74a6-4d74-b0f3-6f42a3c00a90", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.092362, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.356225", "ticker_sentiment_score": "0.079279", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.137671", "ticker_sentiment_score": "0.083136", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome", "url": "https://www.globenewswire.com/news-release/2023/06/16/2689751/0/en/Clearmind-Medicine-and-SciSparc-to-Conduct-Study-Evaluating-Combination-Treatment-for-Obesity-and-Metabolic-Syndrome.html", "time_published": "20230616T130500", "authors": ["Clearmind Medicine Inc."], "summary": "The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide ( PEA ) , the active ingredient of its proprietary ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.098635, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.240149", "ticker_sentiment_score": "0.029916", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.104228", "ticker_sentiment_score": "0.080286", "ticker_sentiment_label": "Neutral"}]}, {"title": "Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome - SciSparc  ( NASDAQ:SPRC ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/06/32891785/exclusive-clearmind-and-scisparc-to-conduct-study-evaluating-psychedelics-and-cannamide-based-dr", "time_published": "20230616T124621", "authors": ["Vuk Zdinjak"], "summary": "Clearmind Medicine Inc. CMND CMND CWY announced that as part of the company's ongoing collaboration with SciSparc Ltd. SPRC, has entered into a research agreement with the Hebrew University of Jerusalem, to evaluate Clearmind's and SciSparc's combination treatment for obesity and metabolic ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/16/louis.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.341627, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.171485", "ticker_sentiment_score": "0.039809", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.254751", "ticker_sentiment_score": "0.054037", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity", "url": "https://www.globenewswire.com/news-release/2023/06/09/2685574/0/en/Clearmind-Medicine-to-Host-Virtual-Investor-Conference-on-Psychedelics-for-Obesity.html", "time_published": "20230609T133000", "authors": ["Clearmind Medicine Inc."], "summary": "The conference will stream live on Monday, June 12, at 10:00 AM EST ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.104402, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.231884", "ticker_sentiment_score": "0.157806", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "MEAI Compound's First Clinical Trial In US, Clearmind Enters NASDAQ Compliance Period - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/05/32513885/meai-compounds-first-clinical-trial-in-us-clearmind-enters-nasdaq-compliance-period", "time_published": "20230522T200301", "authors": ["Lara Goldstein"], "summary": "Clearmind Medicine Inc. CMND, an Israel-based biotech company advancing the clinical stage for an MEAI-based compound targeting Alcohol Use Disorder ( AUD, ) has selected Yale School of Medicine's Psychiatry Dept. as the first U.S. site for its Phase 1/2a trial on proprietary CMND-100.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/22/advanced_technology_clinic_dmt_psilocybin_mdma_bacsica_aiyoshi597_gisele_yashar_and_metamorworks_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.13575, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.076115", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.367141", "ticker_sentiment_score": "0.025732", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification", "url": "https://www.globenewswire.com/news-release/2023/05/19/2672789/0/en/Clearmind-Medicine-Announces-Receipt-of-Nasdaq-Minimum-Bid-Price-Notification.html", "time_published": "20230519T201500", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( NASDAQ: CMND ) ( CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or \"the Company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.961735"}], "overall_sentiment_score": 0.122724, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.243376", "ticker_sentiment_score": "0.217834", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why DXC Technology Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket - Alimera Sciences  ( NASDAQ:ALIM ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/23/05/32483790/why-dxc-technology-shares-are-trading-lower-by-around-5-here-are-20-stocks-moving-premarket", "time_published": "20230519T121734", "authors": ["Lisa Levin"], "summary": "Monogram Orthopaedics Inc. MGRM shares surged 163.7% to $30.98 in pre-market trading after jumping 62% on Thursday. Monogram Orthopaedics raised $17,216,147 through the sale of 2,374,641 shares of its Class A Lucy Scientific Discovery Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/19/dxc_technology_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.157343, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ZVSA", "relevance_score": "0.145145", "ticker_sentiment_score": "0.305465", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FLJ", "relevance_score": "0.145145", "ticker_sentiment_score": "0.159556", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EGIO", "relevance_score": "0.216215", "ticker_sentiment_score": "0.280431", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HILS", "relevance_score": "0.216215", "ticker_sentiment_score": "0.13788", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXC", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.208382", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KPLT", "relevance_score": "0.216215", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSDI", "relevance_score": "0.216215", "ticker_sentiment_score": "0.324564", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALIM", "relevance_score": "0.216215", "ticker_sentiment_score": "0.205304", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ELBM", "relevance_score": "0.145145", "ticker_sentiment_score": "0.159556", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FTCH", "relevance_score": "0.145145", "ticker_sentiment_score": "0.274937", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SOND", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.234624", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ENVB", "relevance_score": "0.216215", "ticker_sentiment_score": "-0.028791", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHIO", "relevance_score": "0.216215", "ticker_sentiment_score": "0.088013", "ticker_sentiment_label": "Neutral"}, {"ticker": "FFIE", "relevance_score": "0.145145", "ticker_sentiment_score": "0.249592", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IFBD", "relevance_score": "0.145145", "ticker_sentiment_score": "-0.234624", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CMND", "relevance_score": "0.285526", "ticker_sentiment_score": "0.057254", "ticker_sentiment_label": "Neutral"}]}, {"title": "Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More - ATAI Life Sciences  ( NASDAQ:ATAI ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/05/32404420/psyched-20m-research-fund-lsd-microdosing-for-cancer-meai-enters-clinical-stage-reform-update-mo", "time_published": "20230515T213048", "authors": ["Lara Goldstein"], "summary": "Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths Ph.D. Professorship Fund. Featured in the New York Times, Griffiths is a psychopharmacologist and professor of neuroscience, psychiatry and behavioral studies.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/15/psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.276775, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NYT", "relevance_score": "0.047278", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUGE", "relevance_score": "0.09439", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPS", "relevance_score": "0.09439", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.141171", "ticker_sentiment_score": "-0.050598", "ticker_sentiment_label": "Neutral"}, {"ticker": "SILO", "relevance_score": "0.09439", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Best Penny Stocks To Buy Now? 7 Under $1 To Watch", "url": "https://pennystocks.com/featured/2023/05/12/best-penny-stocks-to-buy-now-7-under-1-to-watch-may-2023/", "time_published": "20230512T151640", "authors": ["J. Samuel"], "summary": "Inflation data, earnings, and now, the debt ceiling crisis are dominating headlines in the stock market today. However, one of the market segments likely shrugging these \"fears\" off is the one that includes penny stocks.", "banner_image": null, "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.967321"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.166295, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.035661", "ticker_sentiment_score": "0.051514", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATXG", "relevance_score": "0.106699", "ticker_sentiment_score": "0.131774", "ticker_sentiment_label": "Neutral"}, {"ticker": "SUNW", "relevance_score": "0.106699", "ticker_sentiment_score": "0.027404", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSIT", "relevance_score": "0.245693", "ticker_sentiment_score": "0.127138", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSOI", "relevance_score": "0.035661", "ticker_sentiment_score": "0.1907", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.17689", "ticker_sentiment_score": "0.141881", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder", "url": "https://www.globenewswire.com/news-release/2023/05/12/2667849/0/en/Clearmind-Medicine-Announces-IRB-Approval-to-Conduct-Clinical-Trial-on-Alcohol-Use-Disorder.html", "time_published": "20230512T130000", "authors": ["Clearmind Medicine Inc."], "summary": "IMCA medical center's ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.125594, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.514619", "ticker_sentiment_score": "0.241376", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "EXCLUSIVE: Clearmind Medicine Secures Approval To Launch Clinical Trial For Alcohol Addiction Treatment - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/05/32355169/exclusive-clearmind-medicine-secures-approval-to-launch-clinical-trial-for-alcohol-addiction-tre", "time_published": "20230512T123007", "authors": ["Lara Goldstein"], "summary": "Clearmind Medicine Inc. CMND, an Israeli biotech company received approval from the IMCA center's Ethics Committee for the announced Phase 1/2 clinical trial assessing its proprietary MEAI-based compound, CMND-100, for the treatment of Alcohol Use Disorder ( AUD. ) Clearmind discovers and ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/11/financial_psychedelics_raimundo79_and_sergey_nivens_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.344886, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.574748", "ticker_sentiment_score": "0.354691", "ticker_sentiment_label": "Bullish"}]}, {"title": "Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More - Compass Pathways  ( NASDAQ:CMPS ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/05/32270868/psyched-psychedelics-reimbursement-amanita-muscaria-boom-53m-material-breach-lawsuit-more", "time_published": "20230508T202323", "authors": ["Lara Goldstein"], "summary": "The American Medical Association ( AMA ) is expected to issue the first code for psychedelic therapy reimbursement, following the approval of a joint application submitted by MAPS PBC and COMPASS Pathways CMPS.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/08/psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.109101, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HUGE", "relevance_score": "0.169279", "ticker_sentiment_score": "0.094333", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPS", "relevance_score": "0.113329", "ticker_sentiment_score": "0.035169", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.113329", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Next-Gen Israeli Psychedelics Company Gears Up For Trial Targeting Alcohol Addiction - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/05/32193519/next-gen-israeli-psychedelics-company-gears-up-for-trial-targeting-alcohol-addiction", "time_published": "20230503T190425", "authors": ["Lara Goldstein"], "summary": "Alcohol Use Disorder ( AUD ) is one of the top-targeted health issues by biopharma companies. In the case of Clearmind Medicine CMND, the Israel-based company is going at it through its MEAI-based proprietary drug candidate, CMND-100.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/03/financial_psychedelics_raimundo79_and_sergey_nivens_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.252762, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.120431", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.551295", "ticker_sentiment_score": "0.245016", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Meta Platforms Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - American Rebel Holdings  ( NASDAQ:AREB ) , Atomera  ( NASDAQ:ATOM ) ", "url": "https://www.benzinga.com/news/23/04/32043114/why-meta-platforms-shares-are-trading-higher-by-over-11-here-are-20-stocks-moving-premarket", "time_published": "20230427T114104", "authors": ["Lisa Levin"], "summary": "Evelo Biosciences, Inc. EVLO gained 115.4% to $0.2154 in pre-market trading. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its EDP1815 Phase 2 trial, in which the primary endpoint was not met.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/27/facebook_-_logo.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.048232, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.139669", "ticker_sentiment_score": "0.445039", "ticker_sentiment_label": "Bullish"}, {"ticker": "BXRX", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.166003", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "INAB", "relevance_score": "0.208166", "ticker_sentiment_score": "-0.15457", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MGRX", "relevance_score": "0.208166", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EGIO", "relevance_score": "0.139669", "ticker_sentiment_score": "0.299315", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IDEX", "relevance_score": "0.139669", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMMX", "relevance_score": "0.208166", "ticker_sentiment_score": "0.399593", "ticker_sentiment_label": "Bullish"}, {"ticker": "OPGN", "relevance_score": "0.139669", "ticker_sentiment_score": "0.18686", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STM", "relevance_score": "0.070105", "ticker_sentiment_score": "0.063654", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATOM", "relevance_score": "0.139669", "ticker_sentiment_score": "0.078842", "ticker_sentiment_label": "Neutral"}, {"ticker": "AREB", "relevance_score": "0.139669", "ticker_sentiment_score": "0.126955", "ticker_sentiment_label": "Neutral"}, {"ticker": "WINT", "relevance_score": "0.208166", "ticker_sentiment_score": "-0.176815", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EVLO", "relevance_score": "0.208166", "ticker_sentiment_score": "0.183158", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MOBQ", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.146374", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNO", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.002561", "ticker_sentiment_label": "Neutral"}, {"ticker": "UCAR", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.316297", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PI", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.201651", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WOLF", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.253695", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CNMD", "relevance_score": "0.070105", "ticker_sentiment_score": "-0.10347", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETAO", "relevance_score": "0.139669", "ticker_sentiment_score": "0.32114", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GETR", "relevance_score": "0.208166", "ticker_sentiment_score": "-0.121109", "ticker_sentiment_label": "Neutral"}, {"ticker": "IEX", "relevance_score": "0.070105", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.125529", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Chipotle Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session", "url": "https://markets.businessinsider.com/news/stocks/why-chipotle-shares-are-trading-higher-by-13-here-are-other-stocks-moving-in-wednesday-s-mid-day-session-1032264876", "time_published": "20230426T181251", "authors": [], "summary": "Crown ElectroKinetics Corp. ( NASDAQ:CRKN ) shares jumped 105% to $0.1730 after the company issued a letter to shareholders. SAI.TECH Global Corporation ( NASDAQ:SAI ) shares climbed 51.1% to $4.22 after gaining 9% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/04/26/chipotle_mexican_grill_-_logo_0.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.999954"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.081692, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACW", "relevance_score": "0.032338", "ticker_sentiment_score": "0.205433", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RERE", "relevance_score": "0.032338", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BXRX", "relevance_score": "0.064623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRNEQ", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.027705", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRG", "relevance_score": "0.032338", "ticker_sentiment_score": "0.314296", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BBBY", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.055099", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRN", "relevance_score": "0.032338", "ticker_sentiment_score": "0.25214", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDB", "relevance_score": "0.032338", "ticker_sentiment_score": "0.293184", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRKN", "relevance_score": "0.032338", "ticker_sentiment_score": "0.121212", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTKB", "relevance_score": "0.032338", "ticker_sentiment_score": "0.126057", "ticker_sentiment_label": "Neutral"}, {"ticker": "UCAR", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.404273", "ticker_sentiment_label": "Bearish"}, {"ticker": "HOTH", "relevance_score": "0.064623", "ticker_sentiment_score": "-0.15825", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CMG", "relevance_score": "0.032338", "ticker_sentiment_score": "0.202467", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MGIH", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.11141", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLSK", "relevance_score": "0.064623", "ticker_sentiment_score": "0.132173", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACON", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.324368", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TMPO", "relevance_score": "0.032338", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZVSA", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.135767", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSR", "relevance_score": "0.064623", "ticker_sentiment_score": "0.08207", "ticker_sentiment_label": "Neutral"}, {"ticker": "INAB", "relevance_score": "0.064623", "ticker_sentiment_score": "-0.156243", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNOW", "relevance_score": "0.032338", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCON", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.324368", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WLGS", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.324368", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IDEX", "relevance_score": "0.032338", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WIRE", "relevance_score": "0.032338", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASTS", "relevance_score": "0.032338", "ticker_sentiment_score": "0.293184", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HESG", "relevance_score": "0.032338", "ticker_sentiment_score": "0.239181", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BTOG", "relevance_score": "0.032338", "ticker_sentiment_score": "0.293184", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFII", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.388049", "ticker_sentiment_label": "Bearish"}, {"ticker": "ATVI", "relevance_score": "0.032338", "ticker_sentiment_score": "0.0542", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPTN", "relevance_score": "0.032338", "ticker_sentiment_score": "0.095179", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETAO", "relevance_score": "0.032338", "ticker_sentiment_score": "0.15918", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.032338", "ticker_sentiment_score": "0.063674", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAIA", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.324368", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ENPH", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.064667", "ticker_sentiment_label": "Neutral"}, {"ticker": "CXAI", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.324368", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PBLA", "relevance_score": "0.064623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.032338", "ticker_sentiment_score": "0.088361", "ticker_sentiment_label": "Neutral"}, {"ticker": "VICR", "relevance_score": "0.032338", "ticker_sentiment_score": "0.239181", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WNC", "relevance_score": "0.032338", "ticker_sentiment_score": "0.300215", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.064623", "ticker_sentiment_score": "0.174953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EVLO", "relevance_score": "0.032338", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBTS", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.179785", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SPWR", "relevance_score": "0.032338", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MARA", "relevance_score": "0.032338", "ticker_sentiment_score": "0.277137", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HUT", "relevance_score": "0.032338", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRC", "relevance_score": "0.032338", "ticker_sentiment_score": "0.063674", "ticker_sentiment_label": "Neutral"}, {"ticker": "WETG", "relevance_score": "0.064623", "ticker_sentiment_score": "-0.15825", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MANH", "relevance_score": "0.032338", "ticker_sentiment_score": "0.173887", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APLM", "relevance_score": "0.064623", "ticker_sentiment_score": "-0.02414", "ticker_sentiment_label": "Neutral"}, {"ticker": "WULF", "relevance_score": "0.032338", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EPOW", "relevance_score": "0.032338", "ticker_sentiment_score": "0.126057", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.050742", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRC", "relevance_score": "0.032338", "ticker_sentiment_score": "-0.202467", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "USNA", "relevance_score": "0.032338", "ticker_sentiment_score": "0.239181", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIOT", "relevance_score": "0.032338", "ticker_sentiment_score": "0.277137", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SCLX", "relevance_score": "0.096801", "ticker_sentiment_score": "-0.031035", "ticker_sentiment_label": "Neutral"}, {"ticker": "UMBF", "relevance_score": "0.032338", "ticker_sentiment_score": "0.191604", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALTI", "relevance_score": "0.032338", "ticker_sentiment_score": "0.293184", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ODFL", "relevance_score": "0.032338", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.160633", "ticker_sentiment_score": "0.230631", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Bed Bath & Beyond Shares Are Trading Lower By 23%; Here Are 20 Stocks Moving Premarket - Bed Bath & Beyond  ( NASDAQ:BBBY ) , Apollomics  ( NASDAQ:APLM ) ", "url": "https://www.benzinga.com/news/23/04/32009221/why-bed-bath-beyond-shares-are-trading-lower-by-23-here-are-20-stocks-moving-premarket", "time_published": "20230426T123739", "authors": ["Lisa Levin"], "summary": "Clearmind Medicine Inc. CMND gained 61.5% to $0.88 in pre-market trading after dropping around 3% on Tuesday. Clearmind engaged a contract research organization for its upcoming first-in-human study of MEAI compound while also filing an additional provisional patent application with partner ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/26/bed_bath__beyond_-__logo.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.882182"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.060152, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACW", "relevance_score": "0.12645", "ticker_sentiment_score": "0.238613", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ZVSA", "relevance_score": "0.188683", "ticker_sentiment_score": "-0.113899", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENPH", "relevance_score": "0.12645", "ticker_sentiment_score": "-0.191243", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FSR", "relevance_score": "0.188683", "ticker_sentiment_score": "0.170194", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INAB", "relevance_score": "0.188683", "ticker_sentiment_score": "0.026122", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBBY", "relevance_score": "0.12645", "ticker_sentiment_score": "-0.064736", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRC", "relevance_score": "0.063425", "ticker_sentiment_score": "0.122089", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLM", "relevance_score": "0.188683", "ticker_sentiment_score": "-0.033848", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.12645", "ticker_sentiment_score": "0.30043", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IMV", "relevance_score": "0.188683", "ticker_sentiment_score": "-0.195989", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RNAZ", "relevance_score": "0.188683", "ticker_sentiment_score": "0.09008", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBTS", "relevance_score": "0.12645", "ticker_sentiment_score": "-0.194179", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CYTH", "relevance_score": "0.12645", "ticker_sentiment_score": "-0.013864", "ticker_sentiment_label": "Neutral"}, {"ticker": "REAL", "relevance_score": "0.12645", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SONN", "relevance_score": "0.188683", "ticker_sentiment_score": "-0.284434", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ETAO", "relevance_score": "0.12645", "ticker_sentiment_score": "0.171959", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MGIH", "relevance_score": "0.12645", "ticker_sentiment_score": "-0.135232", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLSK", "relevance_score": "0.188683", "ticker_sentiment_score": "0.180538", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.12645", "ticker_sentiment_score": "0.141574", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.063425", "ticker_sentiment_score": "0.122089", "ticker_sentiment_label": "Neutral"}]}, {"title": "SciSparc And Clearmind Collaboration Strengthens IP Portfolio With Patent Application For Treatment Of Depression - SciSparc  ( NASDAQ:SPRC ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/04/31934517/scisparc-and-clearmind-collaboration-strengthens-ip-portfolio-with-patent-application-for-treatm", "time_published": "20230421T131206", "authors": ["Vuk Zdinjak"], "summary": "SciSparc Ltd. SPRC, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its ongoing collaboration with Clearmind Medicine Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/21/scott-graham-oqmzwnd3thu-unsplash4.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.315943, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.290607", "ticker_sentiment_score": "0.198179", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.423843", "ticker_sentiment_score": "0.259757", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression", "url": "https://www.globenewswire.com/news-release/2023/04/21/2651925/0/en/Clearmind-Medicine-Expanding-IP-Portfolio-with-New-US-Patent-Application-for-Treatment-of-Depression.html", "time_published": "20230421T123000", "authors": ["Clearmind Medicine Inc."], "summary": "The application is for a novel psychedelic-based combination, of Clearmind's MEAI and ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.088695, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.183895", "ticker_sentiment_score": "0.052153", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.183895", "ticker_sentiment_score": "0.104843", "ticker_sentiment_label": "Neutral"}]}, {"title": "Psyched Clinical Trials: Australian Univ. Pursues MDMA, MEAI Compound About To Set Off - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/04/31920294/psyched-clinical-trials-australian-univ-pursues-mdma-meai-compound-about-to-set-off", "time_published": "20230420T184804", "authors": ["Lara Goldstein"], "summary": "Australian Monash University's psychedelics research lab has contracted MDXX-class molecules developer PharmAla Biotech to manufacture and supply its clinical-grade MDMA LaNeo for an upcoming Phase 2 clinical study. This is PharmAla's fourth MDMA supply for a major clinical trial in Australia.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/20/psychedelics_earnings_pexels.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.366158, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.236588", "ticker_sentiment_score": "0.092745", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial", "url": "https://www.globenewswire.com/news-release/2023/04/20/2650754/0/en/Clearmind-Medicine-Engages-Experienced-Contract-Research-Organization-to-Support-its-First-in-Human-Clinical-Trial.html", "time_published": "20230420T093700", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, April 20, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( NASDAQ: CMND ) ( CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or \"the company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.093498, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.337811", "ticker_sentiment_score": "0.189614", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Sonnet BioTherapeutics Shares Are Trading Lower By Around 13%; Here Are 20 Stocks Moving Premarket - a.k.a. Brands Holding  ( NYSE:AKA ) , Bed Bath & Beyond  ( NASDAQ:BBBY ) ", "url": "https://www.benzinga.com/news/23/04/31888196/why-sonnet-biotherapeutics-shares-are-trading-lower-by-around-13-here-are-20-stocks-moving-premarket", "time_published": "20230419T121333", "authors": ["Lisa Levin"], "summary": "Clearmind Medicine Inc. CMND jumped 69.3% to $0.8480 in pre-market trading after dropping 12% on Tuesday. Clearmind Medicine recently announced a $3.5 million public offering priced at $0.78 per share. a.k.a. Brands Holding Corp.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/19/sonnet_biotherapeutics_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.180505, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GMDA", "relevance_score": "0.172919", "ticker_sentiment_score": "0.100356", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBLA", "relevance_score": "0.172919", "ticker_sentiment_score": "0.111747", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIOC", "relevance_score": "0.172919", "ticker_sentiment_score": "-0.205191", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BBBY", "relevance_score": "0.172919", "ticker_sentiment_score": "0.059528", "ticker_sentiment_label": "Neutral"}, {"ticker": "UIHC", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.048551", "ticker_sentiment_label": "Neutral"}, {"ticker": "OBLG", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.187035", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MCB", "relevance_score": "0.115787", "ticker_sentiment_score": "0.28067", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GNPX", "relevance_score": "0.115787", "ticker_sentiment_score": "0.348131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LUNR", "relevance_score": "0.229149", "ticker_sentiment_score": "0.377014", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNES", "relevance_score": "0.172919", "ticker_sentiment_score": "0.232236", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WINT", "relevance_score": "0.172919", "ticker_sentiment_score": "-0.032883", "ticker_sentiment_label": "Neutral"}, {"ticker": "SABS", "relevance_score": "0.115787", "ticker_sentiment_score": "0.234858", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SONN", "relevance_score": "0.115787", "ticker_sentiment_score": "-0.249094", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GETR", "relevance_score": "0.172919", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CJJD", "relevance_score": "0.172919", "ticker_sentiment_score": "0.232236", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.172919", "ticker_sentiment_score": "0.108397", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLGG", "relevance_score": "0.172919", "ticker_sentiment_score": "0.197581", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket - IMAC Hldgs  ( NASDAQ:BACK ) , Brenmiller Energy  ( NASDAQ:BNRG ) ", "url": "https://www.benzinga.com/news/23/04/31766625/why-imedia-brands-shares-are-trading-higher-by-over-13-here-are-20-stocks-moving-premarket", "time_published": "20230412T122758", "authors": ["Lisa Levin"], "summary": "HeartCore Enterprises, Inc. HTCR jumped 119.6% to $1.96 in pre-market trading. HeartCore forged an agreement with rYojbaba Inc for its tenth Go IPO consulting service win. Altamira Therapeutics Ltd. CYTO gained 81.8% to $2.40 in pre-market trading after dropping 36% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/12/imedia_brands_-_logo.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.098732, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ZVSA", "relevance_score": "0.148273", "ticker_sentiment_score": "0.309056", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VORB", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.056648", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBLA", "relevance_score": "0.148273", "ticker_sentiment_score": "0.21093", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CIH", "relevance_score": "0.148273", "ticker_sentiment_score": "0.220727", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IMBIL", "relevance_score": "0.07446", "ticker_sentiment_score": "-0.190116", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JSPR", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.199938", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RCLF", "relevance_score": "0.148273", "ticker_sentiment_score": "0.350054", "ticker_sentiment_label": "Bullish"}, {"ticker": "CYTO", "relevance_score": "0.148273", "ticker_sentiment_score": "0.21093", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NUTX", "relevance_score": "0.148273", "ticker_sentiment_score": "0.272733", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLXP", "relevance_score": "0.148273", "ticker_sentiment_score": "-0.21093", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IPDN", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.199938", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SYTA", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.249194", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "YVR", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.185052", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NCMI", "relevance_score": "0.220809", "ticker_sentiment_score": "0.053237", "ticker_sentiment_label": "Neutral"}, {"ticker": "APE", "relevance_score": "0.07446", "ticker_sentiment_score": "0.030803", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNSP", "relevance_score": "0.220809", "ticker_sentiment_score": "0.126879", "ticker_sentiment_label": "Neutral"}, {"ticker": "BACK", "relevance_score": "0.148273", "ticker_sentiment_score": "-0.237468", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HTCR", "relevance_score": "0.148273", "ticker_sentiment_score": "0.173449", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNRG", "relevance_score": "0.148273", "ticker_sentiment_score": "0.171671", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.220809", "ticker_sentiment_score": "0.211672", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why National CineMedia Shares Are Trading Higher By Around 111%; Here Are 20 Stocks Moving Premarket - Agrify  ( NASDAQ:AGFY ) , Brenmiller Energy  ( NASDAQ:BNRG ) ", "url": "https://www.benzinga.com/news/23/04/31741625/why-national-cinemedia-shares-are-trading-higher-by-around-111-here-are-20-stocks-moving-premarket", "time_published": "20230411T122012", "authors": ["Lisa Levin"], "summary": "National CineMedia, Inc. NCMI jumped 111.2% to $0.2810 in pre-market trading after a 13G filing showed a 9.1% passive stake in the company from AMC Entertainment. Innovative Eyewear, Inc. LUCY gained 71.2% to $2.50 in pre-market trading.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/11/national_cinemedia_-_logo.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.106306, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WW", "relevance_score": "0.24289", "ticker_sentiment_score": "0.316298", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CNTG", "relevance_score": "0.24289", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.082111", "ticker_sentiment_score": "-0.277035", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VORB", "relevance_score": "0.24289", "ticker_sentiment_score": "-0.45827", "ticker_sentiment_label": "Bearish"}, {"ticker": "EJH", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.184002", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PEAR", "relevance_score": "0.24289", "ticker_sentiment_score": "0.179858", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CLEU", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.497519", "ticker_sentiment_label": "Bearish"}, {"ticker": "AGFY", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.23576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EBET", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.251749", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GS", "relevance_score": "0.082111", "ticker_sentiment_score": "0.182126", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOGN", "relevance_score": "0.163354", "ticker_sentiment_score": "0.417097", "ticker_sentiment_label": "Bullish"}, {"ticker": "FNCH", "relevance_score": "0.24289", "ticker_sentiment_score": "-0.496349", "ticker_sentiment_label": "Bearish"}, {"ticker": "PLXP", "relevance_score": "0.24289", "ticker_sentiment_score": "-0.255863", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GCTK", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.251749", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HEXO", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.23576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NCMI", "relevance_score": "0.163354", "ticker_sentiment_score": "0.101625", "ticker_sentiment_label": "Neutral"}, {"ticker": "APE", "relevance_score": "0.082111", "ticker_sentiment_score": "0.077484", "ticker_sentiment_label": "Neutral"}, {"ticker": "KAL", "relevance_score": "0.163354", "ticker_sentiment_score": "0.016853", "ticker_sentiment_label": "Neutral"}, {"ticker": "TLRY", "relevance_score": "0.082111", "ticker_sentiment_score": "-0.180067", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HSCS", "relevance_score": "0.24289", "ticker_sentiment_score": "-0.473664", "ticker_sentiment_label": "Bearish"}, {"ticker": "LUCY", "relevance_score": "0.24289", "ticker_sentiment_score": "0.441096", "ticker_sentiment_label": "Bullish"}, {"ticker": "ZFOX", "relevance_score": "0.24289", "ticker_sentiment_score": "-0.474741", "ticker_sentiment_label": "Bearish"}, {"ticker": "BNRG", "relevance_score": "0.163354", "ticker_sentiment_score": "0.369854", "ticker_sentiment_label": "Bullish"}, {"ticker": "CMND", "relevance_score": "0.163354", "ticker_sentiment_score": "0.198317", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Closes US$3.5 Million Public Offering", "url": "https://www.globenewswire.com/news-release/2023/04/06/2642995/0/en/Clearmind-Medicine-Closes-US-3-5-Million-Public-Offering.html", "time_published": "20230406T201500", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, April 06, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( NASDAQ: CMND ) ( CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" ) , a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.875462"}], "overall_sentiment_score": 0.090256, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.176502", "ticker_sentiment_score": "0.127296", "ticker_sentiment_label": "Neutral"}]}, {"title": "How To Finance A Psychedelics Business? Learn From These Four Companies - Algernon Pharmaceuticals  ( OTC:AGNPF ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/04/31666193/how-to-finance-a-psychedelics-business-learn-from-these-four-companies", "time_published": "20230404T204142", "authors": ["Lara Goldstein"], "summary": "Israeli biotech company Clearmind Medicine Inc. CMND announced the pricing of its US-only public offering of 4.6 million common shares and pre-funded warrants and 4.5 million common warrants for expected gross proceeds of approximately $3.5 million.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/04/stocks_psychedelics_3_pexels.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.220413, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.143415", "ticker_sentiment_score": "-0.030651", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Tumbles Over 200 Points; Butterfly Network Shares Spike Higher - Bullfrog AI Hldgs  ( NASDAQ:BFRG ) , Butterfly Network  ( NYSE:BFLY ) ", "url": "https://www.benzinga.com/news/earnings/23/04/31664410/dow-tumbles-over-200-points-butterfly-network-shares-spike-higher", "time_published": "20230404T183314", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 200 points on Tuesday. The Dow traded down 0.64% to 33,387.61 while the NASDAQ fell 0.45% to 12,134.09. The S&P 500, also fell, dropping, 0.54% to 4,102.27. Utilities shares rose by 0.3% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/04/image46.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.079327, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CDLX", "relevance_score": "0.137671", "ticker_sentiment_score": "0.364306", "ticker_sentiment_label": "Bullish"}, {"ticker": "KEN", "relevance_score": "0.137671", "ticker_sentiment_score": "0.179344", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ONCT", "relevance_score": "0.137671", "ticker_sentiment_score": "0.101467", "ticker_sentiment_label": "Neutral"}, {"ticker": "BFRG", "relevance_score": "0.137671", "ticker_sentiment_score": "0.179344", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOGN", "relevance_score": "0.205225", "ticker_sentiment_score": "0.288212", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BFLY", "relevance_score": "0.137671", "ticker_sentiment_score": "0.202479", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.205225", "ticker_sentiment_score": "0.138564", "ticker_sentiment_label": "Neutral"}, {"ticker": "CWCO", "relevance_score": "0.137671", "ticker_sentiment_score": "0.179344", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.069094", "ticker_sentiment_score": "-0.09508", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gold Rises Sharply; AMC Entertainment Shares Plunge - AeroVironment  ( NASDAQ:AVAV ) , AMC Enter Hldgs  ( NYSE:AMC ) ", "url": "https://www.benzinga.com/news/earnings/23/04/31661623/gold-rises-sharply-amc-entertainment-shares-plunge", "time_published": "20230404T160858", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 150 points on Tuesday. The Dow traded down 0.46% to 33,447.10 while the NASDAQ fell 0.30% to 12,152.44. The S&P 500, also fell, dropping, 0.35% to 4 4,110.24. Health care shares jumped by 0.4% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/04/gold-image.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.159782, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AYI", "relevance_score": "0.197413", "ticker_sentiment_score": "0.019092", "ticker_sentiment_label": "Neutral"}, {"ticker": "EHC", "relevance_score": "0.132368", "ticker_sentiment_score": "0.303273", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CDLX", "relevance_score": "0.132368", "ticker_sentiment_score": "0.357555", "ticker_sentiment_label": "Bullish"}, {"ticker": "AVAV", "relevance_score": "0.132368", "ticker_sentiment_score": "0.435477", "ticker_sentiment_label": "Bullish"}, {"ticker": "APE", "relevance_score": "0.132368", "ticker_sentiment_score": "0.392643", "ticker_sentiment_label": "Bullish"}, {"ticker": "BFRG", "relevance_score": "0.132368", "ticker_sentiment_score": "0.175771", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOGN", "relevance_score": "0.197413", "ticker_sentiment_score": "0.280247", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BFLY", "relevance_score": "0.132368", "ticker_sentiment_score": "0.303273", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.197413", "ticker_sentiment_score": "0.134541", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.094629", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Clearmind Medicine Shares Are Nosediving - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/23/04/31660149/why-clearmind-medicine-shares-are-nosediving", "time_published": "20230404T155253", "authors": ["Henry Khederian"], "summary": "Clearmind Medicine Inc CMND shares are trading lower by 60.1% to $0.57 Tuesday morning after the company announced a $3.5 million public offering priced at $0.78 per share. The offering is expected to close on April 6, subject to the satisfaction of customary closing conditions.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/04/analysis-4937349.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.136223, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.895116", "ticker_sentiment_score": "0.190444", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More - Filament Health  ( OTC:FLHLF ) , AdvisorShares Psychedelics ETF  ( ARCA:PSIL ) , Field Trip Health  ( OTC:FTHWF ) , FSD Pharma  ( NASDAQ:HUGE ) , Reunion Neuroscience  ( NASDAQ:REUN ) , Lucy Scientific Discovery  ( NASDAQ:LSDI ) , Delic Hldgs  ( OTC:DELCF ) , ETF Series Solutions PSYK ETF  ( ARCA:PSYK ) , Incannex Healthcare  ( NASDAQ:IXHL ) , Red Light Holland  ( OTC:TRUFF ) , Compass Pathways  ( NASDAQ:CMPS ) , Enveric Biosciences  ( NASDAQ:ENVB ) , Braxia Scientific  ( OTC:BRAXF ) , Mindset Pharma  ( OTC:MSSTF ) , Irwin Naturals  ( OTC:IWINF ) , Clearmind Medicine  ( NASDAQ:CMND ) , SILO Pharma  ( NASDAQ:SILO ) ", "url": "https://www.benzinga.com/markets/cannabis/23/03/31428098/psyched-22-states-with-reform-bills-ketamine-therapy-services-today-oscars-on-shrooms-more", "time_published": "20230320T211105", "authors": ["Lara Goldstein"], "summary": "In the first months of 2023, state-level psychedelics policy reform has been so constant that it is hard to view it as a passing trend. While the first reported legalization proposal was a pre-filed measure in New York, many states have then followed suit. The list is current as of March 13.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/20/psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.082626, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DELCF", "relevance_score": "0.082393", "ticker_sentiment_score": "0.069512", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPS", "relevance_score": "0.082393", "ticker_sentiment_score": "-0.258578", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ENVB", "relevance_score": "0.082393", "ticker_sentiment_score": "-0.03841", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRAXF", "relevance_score": "0.082393", "ticker_sentiment_score": "0.129781", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTHWF", "relevance_score": "0.082393", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUGE", "relevance_score": "0.082393", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REUN", "relevance_score": "0.082393", "ticker_sentiment_score": "0.00417", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.082393", "ticker_sentiment_score": "-0.18016", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LSDI", "relevance_score": "0.082393", "ticker_sentiment_score": "0.219331", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SILO", "relevance_score": "0.041251", "ticker_sentiment_score": "0.083829", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Drug That Mimics Alcohol Buzz Is Bound For Human Trials: Here's What's Next - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/03/31386157/a-drug-that-mimics-alcohol-buzz-is-bound-for-human-trials-heres-whats-next", "time_published": "20230317T153021", "authors": ["Lara Goldstein"], "summary": "Israeli biotech Clearmind Medicine Inc. CMND has submitted an Investigational New Drug ( IND ) application with the FDA towards approval to commence its first-in-human Phase 1/2a clinical trial with MEAI-based CMND-100 in patients diagnosed with Alcohol Use Disorder ( AUD ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/16/psychedelics_rd_drug_development_2.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [], "overall_sentiment_score": 0.111532, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.544495", "ticker_sentiment_score": "0.406097", "ticker_sentiment_label": "Bullish"}]}, {"title": "Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board", "url": "https://www.globenewswire.com/news-release/2023/03/14/2626683/0/en/Clearmind-Medicine-Appoints-Professor-Henry-R-Kranzler-M-D-to-Scientific-Advisory-Board.html", "time_published": "20230314T125500", "authors": ["Clearmind Medicine Inc."], "summary": "Professor Kranzler is the Benjamin Rush Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania's Perelman School of Medicine ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.13481, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.187827", "ticker_sentiment_score": "0.131178", "ticker_sentiment_label": "Neutral"}]}, {"title": "US Stocks Mostly Higher; Dow Rises 75 Points - Bluegreen Vacations  ( NYSE:BVH ) , Calliditas Therapeutics  ( NASDAQ:CALT ) ", "url": "https://www.benzinga.com/news/earnings/23/03/31321718/us-stocks-mostly-higher-dow-rises-75-points", "time_published": "20230313T141541", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 75 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 31,986.55 while the NASDAQ rose 0.24% to 11,165.62. The S&P 500, meanwhile, fell, dropping, 0.03% to 3,860.50.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/13/image22.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.019435, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "UBP", "relevance_score": "0.073321", "ticker_sentiment_score": "0.155382", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GGE", "relevance_score": "0.146025", "ticker_sentiment_score": "0.192775", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BVH", "relevance_score": "0.217508", "ticker_sentiment_score": "0.058886", "ticker_sentiment_label": "Neutral"}, {"ticker": "CUBI", "relevance_score": "0.146025", "ticker_sentiment_score": "-0.166533", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FRC", "relevance_score": "0.146025", "ticker_sentiment_score": "0.20533", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.073321", "ticker_sentiment_score": "0.165512", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CALT", "relevance_score": "0.146025", "ticker_sentiment_score": "0.284115", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PRVB", "relevance_score": "0.146025", "ticker_sentiment_score": "0.225398", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SBNY", "relevance_score": "0.146025", "ticker_sentiment_score": "-0.146871", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.146025", "ticker_sentiment_score": "0.438021", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNY", "relevance_score": "0.073321", "ticker_sentiment_score": "0.181728", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SciSparc And Clearmind Reveal Three Unique Combinations Of Future Psychedelic-Based Compounds - SciSparc  ( NASDAQ:SPRC ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/02/31010075/scisparc-and-clearmind-reveal-three-unique-combinations-of-future-psychedelic-based-compounds", "time_published": "20230222T160646", "authors": ["Vuk Zdinjak"], "summary": "SciSparc Ltd. SPRC, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its ongoing collaboration with Clearmind Medicine Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/22/psychedelics_deals_geralt_sergeitokmakov_by_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.153495, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.249106", "ticker_sentiment_score": "0.159982", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.366061", "ticker_sentiment_score": "0.214588", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US - SciSparc  ( NASDAQ:SPRC ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/02/30929361/novel-combination-of-cannabis-like-compound-with-classical-psychedelics-searches-ip-coverage-in-", "time_published": "20230215T174708", "authors": ["Lara Goldstein"], "summary": "Israeli-based next-gen psychedelics biotech Clearmind Medicine CMND together with partner clinical-stage pharma company SciSparc SPRC has filed three provisional patent applications with the United States Patent and Trademark Office ( USPTO ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/02/15/psychedelic_chemistry_olia_danilevich_by_pexels_-_copy.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.272095, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.188193", "ticker_sentiment_score": "0.125523", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.188193", "ticker_sentiment_score": "0.125523", "ticker_sentiment_label": "Neutral"}]}, {"title": "EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead", "url": "https://www.benzinga.com/markets/cannabis/23/02/30647634/exclusive-next-generation-psychedelics-meai-the-road-ahead", "time_published": "20230201T155133", "authors": ["Lara Goldstein"], "summary": "Clearmind Medicine CMND's CEO Dr. Adi Zuloff-Shani has said that she believes MEAI can potentially be consumed on a regular basis over time. \"I can't say now if it'll be for several months, for a year or for a lifetime, but certainly for a few months,\" Zuloff-Shani told Benzinga.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/31/financial_psychedelics_raimundo79_and_sergey_nivens_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.195152, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.101582", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.101582", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results", "url": "https://www.benzinga.com/markets/cannabis/23/01/30647483/israeli-biotech-develops-ketamine-analogue-to-treat-major-depression-with-promising-results", "time_published": "20230131T165857", "authors": ["Lara Goldstein"], "summary": "Israeli-based psychedelics biotech Clearmind Medicine Inc. CMND and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained positive results from the latest preclinical trial on a next-gen psychedelic for the treatment of Major ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/31/psychedelic_chemistry_olia_danilevich_by_pexels_-_copy.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [], "overall_sentiment_score": 0.012333, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.224903", "ticker_sentiment_score": "-0.081851", "ticker_sentiment_label": "Neutral"}]}, {"title": "Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More", "url": "https://www.benzinga.com/markets/cannabis/23/01/30548708/psyched-states-with-psychedelics-legalization-bills-next-gen-molecule-for-addiction-treatment-an", "time_published": "20230125T170257", "authors": ["Lara Goldstein"], "summary": "Legislators in seven U.S. states are introducing psychedelics bills as they seek to emulate measures that have been approved in Oregon and Colorado. From state-regulated psychedelic therapy programs to the legalization of Schedule I substances, the spectrum is broad.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/24/psyched.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [], "overall_sentiment_score": 0.186483, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.082677", "ticker_sentiment_score": "0.057107", "ticker_sentiment_label": "Neutral"}]}, {"title": "EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When", "url": "https://www.benzinga.com/markets/cannabis/23/01/30531250/exclusive-next-generation-psychedelics-meai-what-and-when", "time_published": "20230124T203246", "authors": ["Lara Goldstein"], "summary": "MEAI is a potent synthetic molecule essentially developed in the form of a powder. Nonetheless, for its Alcohol Use Disorder ( AUD ) study, developer Clearmind Medicine CMND will create a hard-gel capsule so that the clinical trial participants can self-administer the psychedelic.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/23/financial_psychedelics_raimundo79_and_sergey_nivens_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.103997, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.085936", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.170878", "ticker_sentiment_score": "-0.028781", "ticker_sentiment_label": "Neutral"}]}, {"title": "EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains", "url": "https://www.benzinga.com/markets/cannabis/23/01/30508635/exclusive-next-generation-psychedelics-meai-how-and-why-an-israeli-scientist-explains", "time_published": "20230123T162750", "authors": ["Lara Goldstein"], "summary": "Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction A compound developed by Israeli psychedelics company Clearmind Medicine CMND would act by providing a similar feeling to that which drinking alcohol produces.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/20/financial_psychedelics_raimundo79_and_sergey_nivens_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.148223, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APG", "relevance_score": "0.057767", "ticker_sentiment_score": "0.066017", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSTK", "relevance_score": "0.057767", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.115232", "ticker_sentiment_score": "0.074481", "ticker_sentiment_label": "Neutral"}]}, {"title": "Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction", "url": "https://www.benzinga.com/markets/cannabis/23/01/30484920/next-generation-psychedelics-the-case-of-meai-and-its-potential-to-treat-addiction", "time_published": "20230120T142953", "authors": ["Lara Goldstein"], "summary": "Increasing evidence of psychedelics' potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to major innovative heights.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/19/financial_psychedelics_raimundo79_and_sergey_nivens_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.160117, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSTK", "relevance_score": "0.085936", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.170878", "ticker_sentiment_score": "0.07847", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects", "url": "https://www.benzinga.com/markets/cannabis/23/01/30490764/clearmind-teams-with-yissum-university-of-jerusalem-on-2-psychedelic-r-d-projects", "time_published": "20230119T195703", "authors": ["Lara Goldstein"], "summary": "Psychedelics biotech Clearmind Medicine Inc. CMND has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/19/psychedelics_ma_pexels.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.292938, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BSX", "relevance_score": "0.244109", "ticker_sentiment_score": "0.202019", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.244109", "ticker_sentiment_score": "0.202019", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.244109", "ticker_sentiment_score": "0.394452", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.244109", "ticker_sentiment_score": "0.202019", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Envisioning A Cocaine-Addiction Treatment: This Next-Gen Psychedelic Shows Positive Results", "url": "https://www.benzinga.com/markets/cannabis/23/01/30462564/envisioning-a-cocaine-addiction-treatment-this-next-gen-psychedelic-shows-positive-results", "time_published": "20230118T171922", "authors": ["Lara Goldstein"], "summary": "Israel-based psychedelics biotech Clearmind Medicine Inc. CMND shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical study of cocaine addiction.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/18/psychedelics_rd_drug_development_2.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.34128, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.185306", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.185306", "ticker_sentiment_score": "0.466704", "ticker_sentiment_label": "Bullish"}]}, {"title": "5 Penny Stocks To Watch After Big News This Week", "url": "https://pennystocks.com/featured/2023/01/17/5-penny-stocks-to-watch-after-big-news-this-week-january-17/", "time_published": "20230117T142414", "authors": ["J. Samuel"], "summary": "It's a new week of the New Year, and traders have high hopes for a January rebound. The exciting part about penny stocks, in particular, is they tend to move independently of broader market trends. That is to say, when the stock market is down, there's usually no shortage of cheap stocks ...", "banner_image": null, "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.187609, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.115787", "ticker_sentiment_score": "0.101425", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLXT", "relevance_score": "0.077343", "ticker_sentiment_score": "0.1066", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.077343", "ticker_sentiment_score": "0.15316", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.038717", "ticker_sentiment_score": "0.11914", "ticker_sentiment_label": "Neutral"}]}, {"title": "Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial", "url": "https://www.globenewswire.com/news-release/2023/01/10/2586168/0/en/Israel-Based-Clearmind-Medicine-Successfully-Completes-Production-of-CMND-100-Drug-Candidate-for-Clinical-Trial.html", "time_published": "20230110T133000", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) ( CSE: CMND ) ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.113983, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.34729", "ticker_sentiment_score": "0.271842", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials - SciSparc  ( NASDAQ:SPRC ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/23/01/30298760/this-original-psychedelic-based-obesity-treatment-set-to-first-in-human-trials", "time_published": "20230106T184507", "authors": ["Lara Goldstein"], "summary": "Psychedelics biopharma company Clearmind Medicine Inc. CMND and clinical-stage firm SciSparc Ltd. SPRC shared the initial positive pre-clinical results of Clearmind's novel psychedelic molecule, MEAI, for the treatment of obesity and potential treatment of metabolic syndromes.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/05/psychedelic_chemistry_olia_danilevich_by_pexels_-_copy.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.198362, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SPRC", "relevance_score": "0.130571", "ticker_sentiment_score": "0.256425", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.130571", "ticker_sentiment_score": "0.256425", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Medicine Announces Shareholders Meeting Results", "url": "https://www.globenewswire.com/news-release/2022/12/29/2580543/0/en/Clearmind-Medicine-Announces-Shareholders-Meeting-Results.html", "time_published": "20221229T110000", "authors": ["Clearmind Medicine Inc."], "summary": "Tel Aviv, Israel / Vancouver, Canada, Dec. 29, 2022 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq, CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.298128, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.414559", "ticker_sentiment_score": "0.430141", "ticker_sentiment_label": "Bullish"}]}, {"title": "Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder", "url": "https://www.globenewswire.com/news-release/2022/12/28/2580269/0/en/Israel-Based-Clearmind-Medicine-Announces-First-Clinical-Center-to-Join-Its-Clinical-Trial-for-Alcohol-Use-Disorder.html", "time_published": "20221228T140000", "authors": ["Clearmind Medicine Inc."], "summary": "Company engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in the United States as well ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.120151, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.235823", "ticker_sentiment_score": "0.096832", "ticker_sentiment_label": "Neutral"}]}, {"title": "Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment - Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/22/12/30110616/israeli-psychedelics-biotech-shares-latest-advancements-moves-forward-with-addictions-treatment", "time_published": "20221219T152824", "authors": ["Lara Goldstein"], "summary": "Psychedelics company Clearmind Medicine Inc. CMND aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for next-generation novel drug candidates, according to CEO Adi Zuloff-Shani.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/16/chemist-gc6eefce49_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "IPO", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.131531, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.457977", "ticker_sentiment_score": "0.093095", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Tumbles Over 500 Points; ECB Raises Rates By 50 bps - Azure Power Global  ( NYSE:AZRE ) , Genie Energy  ( NYSE:GNE ) ", "url": "https://www.benzinga.com/news/earnings/22/12/30093755/dow-tumbles-over-500-points-ecb-raises-rates-by-50-bps", "time_published": "20221215T150950", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower this morning, with the Dow Jones dropping more than 500 points after the Federal Reserve raised interest rates by 50 bps on Wednesday. Following the market opening Thursday, the Dow traded down 1.62% to 33,417.56 while the NASDAQ fell 1.97% to 10,951.28.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/15/image30_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": -0.10594, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "THRD", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.114753", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZRE", "relevance_score": "0.114682", "ticker_sentiment_score": "-0.035741", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNE-P-A", "relevance_score": "0.05749", "ticker_sentiment_score": "-0.030246", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMV", "relevance_score": "0.114682", "ticker_sentiment_score": "0.268414", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVAX", "relevance_score": "0.114682", "ticker_sentiment_score": "0.105605", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.171282", "ticker_sentiment_score": "0.148191", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.114682", "ticker_sentiment_score": "0.115672", "ticker_sentiment_label": "Neutral"}]}, {"title": "Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute", "url": "https://www.globenewswire.com/news-release/2022/12/09/2571107/0/en/Israeli-Biotech-Clearmind-Medicine-Appoints-ex-Red-Bull-Executive-Special-Advisor-for-Developing-MEAI-as-Alcohol-Substitute.html", "time_published": "20221209T140200", "authors": ["Clearmind Medicine Inc."], "summary": "Nicholas Kadysh, a former Red Bull Canada and Juul Labs Canada executive, is an expert on regulatory issues ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.132601, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "III", "relevance_score": "0.05339", "ticker_sentiment_score": "0.103689", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.312158", "ticker_sentiment_score": "0.235847", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Clearmind Gears Up For Clinical Trial To Test Drug That Treats Alcohol Addiction - Clearmind Medicine Inc. - Common Shares  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/markets/cannabis/22/11/29842354/clearmind-gears-up-for-clinical-trial-to-test-drug-that-treats-alcohol-addiction", "time_published": "20221123T202214", "authors": ["Lara Goldstein"], "summary": "Israeli psychedelics biotech Clearmind Medicine Inc. CMND is commencing the production of its proprietary drug candidate based on the MEAI molecule. It will be used in the upcoming Phase 1 clinical trial assessing the treatment of Alcohol Use Disorder ( AUD ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/11/23/adam-wilson-6uionphza5o-unsplash.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [], "overall_sentiment_score": -0.01674, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.412861", "ticker_sentiment_score": "0.26961", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cannabis Deal Tracker: Investment and M&A Activity in the Cannabis Industry November 14th, 2022 - November 18th, 2022", "url": "https://www.investorideas.com/news/2022/cannabis/11231DealTracker.asp", "time_published": "20221123T190700", "authors": [], "summary": "Cannabis Deal Tracker: Investment and M&A Activity in the Cannabis Industry November 14th, 2022 - November ...", "banner_image": null, "source": "Investor Ideas", "category_within_source": "n/a", "source_domain": "www.investorideas.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.972193"}], "overall_sentiment_score": 0.111398, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CGC", "relevance_score": "0.018525", "ticker_sentiment_score": "0.012858", "ticker_sentiment_label": "Neutral"}, {"ticker": "CEJOF", "relevance_score": "0.055535", "ticker_sentiment_score": "0.115983", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.074001", "ticker_sentiment_score": "0.138285", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial", "url": "https://www.globenewswire.com/news-release/2022/11/23/2561628/0/en/Clearmind-Announces-Initiation-of-CMND-100-Manufacturing-Program-to-Address-its-Upcoming-Clinical-Trial.html", "time_published": "20221123T134500", "authors": ["Clearmind Medicine Inc."], "summary": "VANCOUVER, Nov. 23, 2022 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( CSE: CMND ) , ( FSE: CWY ) ( \"Clearmind\" or the \"Company\" ) , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/130d7733-5794-4a6b-92bb-1eee23c524f3?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.081624, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.380736", "ticker_sentiment_score": "0.134509", "ticker_sentiment_label": "Neutral"}]}, {"title": "Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial - Clearmind Medicine Inc. - Common Shares  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/pressreleases/22/11/g29838706/clearmind-announces-initiation-of-cmnd-100-manufacturing-program-to-address-its-upcoming-clinical-", "time_published": "20221123T134500", "authors": ["Globe Newswire"], "summary": "VANCOUVER, Nov. 23, 2022 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc.", "banner_image": "", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.07194, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMND", "relevance_score": "0.379291", "ticker_sentiment_score": "0.123445", "ticker_sentiment_label": "Neutral"}]}]}